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Chronic arsenic exposure is a risk factor for the development of pulmonary 
diseases, including lung cancer, but the exact mechanism is not yet fully understood. 
Many previous studies have relied on acute arsenic exposure (i.e. 1-10 uM arsenic for 
24 hours) to study arsenic toxicological effects. However, acute exposure does not 
reflect the levels or duration of arsenic associated with environmental exposure, or 
drinking of contaminated well water. This dissertation differentiates the effects of acute 
versus chronic arsenic exposures on the EGFR signaling axis and suggests possible 
mechanisms for chronic arsenic-induced pulmonary diseases. The EGFR is a receptor 
tyrosine kinase localized on the cell surface. Overexpression of the EGFR has been 
used as biomarkers for many different types of cancers, including lung cancer. There is 
a strong association between arsenic and lung cancer development, although the clear 
mechanism is still elusive. I hypothesized that chronic exposure of an environmentally 
relevant level of arsenic disrupts the EGFR signaling axis. To test this, a non-malignant 
human bronchial epithelial cell line (BEAS-2B) was exposed to 100 nM arsenite for 24 
weeks. I first differentiated the impact of acute versus chronic arsenic exposure on the 
EGFR signaling axis. Both acute and chronic arsenic exposure increased EGFR protein 
expression level, but only chronic exposure increased EGFR activity, increased 
transcription and protein levels of TGFα. Next, I assessed the functional effects of  
v		
chronic arsenic exposure in BEAS-2B cells and measured EGFR dependency in chronic 
arsenic exposure-induced increased cell migratory ability, which may contribute to 
identifying a novel therapeutic target for arsenic-induced lung carcinogenesis. The 
dissertation proposes novel roles of acute and chronic arsenic on the EGFR signaling 
axis and potential mechanisms of chronic arsenic-induced lung diseases, such as lung 
cancer. It concludes that acute and chronic arsenic exposure impact the EGFR signaling 
axis in different mechanistic pathways, and chronic arsenic exposure increases cell 
migration in both EGFR-dependent and independent mechanisms. 
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Arsenic is a powerful poison, owing to its lack of color, taste and odor [1]. It is 
ranked number one on the Agency for Toxic Substances and Disease Registry (ATSDR) 
Substance Priority List [1]. In 1973, arsenic was classified as group I “carcinogenic to 
humans” by the International Agency for Research on Cancer (IARC) based on 
epidemiological evidence in human and animal models [2-4]. Arsenic is ubiquitous in the 
environment, including air, soil, and water. Arsenic levels in the air and soil are difficult to 
measure and are not regulated by the U.S. Environmental Protection Agency (EPA) due 
to limited and/or transient human exposure. However, the EPA and the World Health 
Organization (WHO) have both set a maximum contaminant level of arsenic in drinking 
water to 10 ppb [5]. Despite this guideline, there are more than 200 million people 
around the world routinely exposed to levels of arsenic that exceed 10 ppb and are at 
risk of adverse health effects from arsenic exposure [6]. 
i. Arsenic Uses in Medical Applications
Arsenic is a double-edged sword, as it has been used for medical applications 
(Fig. 1). In the 18th century, Thomas Fowler, an English physician, produced Fowler’s 
Solution, a potassium bicarbonate-based arsenic solution, which was widely used to 
treat many conditions such as asthma, convulsions [7] and psoriasis [8]. Arsenic was 
also used to treat leukemia. With the Fowler’s Solution, the number of white blood cells 
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Figure 1. Arsenic is a double-edged sword.  
Arsenic is now a well-established carcinogen and is prominently associated with skin, 
lung, and bladder cancers.  Arsenic is also used in medical applications, especially as a 
treatment for leukemia. Despite its effectiveness, over time, carcinogenicity was 
observed in patients who had received arsenic treatment. Thus, its usage declined, but 
due to its potency in medical applications, it is under investigation for the treatment for 
other diseases.  
Arsenic: A Double-Edged Sword 
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declined dramatically in leukemia patients over 10-weeks treatment period [9]. 
Discontinuation of the therapy, however, led to clinical relapse within few weeks. 
Because of its anti-leukemic ability, arsenic was approved by the U.S. Food and Drug 
Administration (FDA) in 2001 for the treatment of acute promylelocytic leukemia (APL) 
[10], and is under investigation for the treatment of other cancer types [11-13].  
Arsenic hinders repair processes of UV-induced photoadducts [14-17], and its 
role in repressing DNA repair processes also contributes to chemotherapeutic effect. 
Wang et al. showed the combination treatment of arsenic with cisplatin is more effective 
in treating hepatocellular carcinoma than cisplatin treatment alone [18]. Another study 
showed that co-treatment of arsenic with cisplatin suppressed cisplatin-induced 
xeroderma pigmentosum group C (XPC) expression by sensitizing wild-type p53 cells, 
inhibiting the repair pathway [19], which enhanced the chemotherapeutic effect. Overall, 
such characteristics of arsenic support its role in chemotherapy and not only human 
toxicity. 
Health Consequences of Acute and Chronic Arsenic Exposure 
The deleterious effects of arsenic are highly dependent on its dose and duration 
of exposure as acute and chronic toxicities present differently. According to EPA 
Terminology Services (TS), acute exposure is defined as an exposure for 24 hours or 
less, and chronic exposure is defined as an exposure lasting 6 months to a lifetime [20]. 
There are also subacute and subchronic exposures. Subacute exposure is an exposure 
between 24 hours and 28 days, and subchronic exposure is a continuous exposure up to 
90 days [21].  
The acute and chronic arsenic toxicological effects on human health are 
summarized in Table 1. The sources of acute and chronic exposure vary, as do their 
biological effects on the body. Usually acute toxicity results from accidental ingestion of 
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high levels of arsenic, such as workers who ingest high levels of arsenic in their 
workplaces from dust and fumes. Ingestion of large amounts of arsenic requires 
treatment, such as administration of intravenous fluids, and chelation therapy to 
accelerate the excretion of arsenic. The symptoms include diarrhea, vomiting, 
dehydration, and hypotension (Table 1). In severe cases, the symptoms can lead to 
death, primarily due to dehydration and shock [22]. To determine the degree of acute 
exposure to arsenic, several tests can be performed, including blood and urine tests. 
The blood test, however, is useful only for 2-4 hours after initial exposure due to rapid 
clearance from the blood [1]. At later times, a more accurate measurement could be 
determined by performing a urine test. A study of individuals who ingested arsenite (a 
trivalent form of arsenic) containing drinking water revealed that 33% of arsenic was 
excreted in the urine within 48 hours, and 45% within 4 days [23].  
Chronic toxicity refers to people who are exposed to low levels of arsenic over a 
long period of time, such as workers in construction, ore smelting, or the semiconductor 
industry or those that consume tainted drinking water. The skin, lungs, and liver are the 
main target sites, as arsenite, especially, readily interacts with thiol or sulfhydryl groups 
in tissue proteins of the organs [24]. The reaction between arsenic and thiol groups can 
alter protein conformation and function [25]. Symptoms include skin lesions, pulmonary 
disease, cardiovascular disease, diabetes, neurological disorders, cancer, and death 
(Table 1) [24, 26, 27]. Typically, epithelial cells have a high content of cysteine residues 
to help target proteins at the cell surface [28, 29]. Arsenic accumulates at those locations 
due to its reactivity with thiol groups of cysteine residues [30, 31]. Thus, for chronic 
arsenic exposure, usually hair and nail analyses are reliable sources to measure the 
time of exposure. Further, the high thiol content of hair and nails causes the 
accumulation of arsenite in those tissues and makes them a reliable source for 
measuring cumulative arsenic levels. In individuals who have no known exposure,  
5	
Table 1. Toxicological effects of acute versus chronic arsenic exposure. 












• Skin lesions and pigment changes
• Neurological disorders
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arsenic concentrations in hair ranges from 0.02 to 0.2 mg/kg [32-38]. In areas with high 
concentrations of arsenic in drinking water (>50 µg/L), the arsenic hair level ranges from 
3 to 10 mg/kg [39]. Chelation therapy can be used to mitigate chronic arsenic toxicity, 
but chronic arsenic exposure can cause many irreversible changes in organs and 
tissues. Currently, there is no known effective treatment leading to an elevated mortality 
rate [40, 41].  
We observed an increased EGFR protein expression level from both acute and 
chronic arsenic exposure, but EGFR activity levels were significantly different depending 
on exposure time [42], which may suggest distinct mechanisms between acute and 
chronic arsenic exposure. It is not unexpected that acute and chronic toxicities result 
from two distinct mechanisms, because 1) different biochemical mechanisms may occur 
in different tissues and organs, and/or 2) different duration time of exposure at the same 
organ may trigger different biological responses. Therefore, depending on dose and 
duration of exposure, arsenic can differently affect many different types of tissues and 
organs causing adverse health effects [43].  
Arsenic in Drinking Water 
As mentioned above, due to its toxicity and the frequency of human exposure, 
arsenic is ranked number one on the ATSDR Substance Priority List, and its 
environmental contamination is a global issue. Although the Environmental Protection 
Agency (EPA) has set the standard for arsenic in municipal drinking water of 10 ppb 
(parts per billion), which is approximately 133 nM, we are still exposed to low levels of 
arsenic on a daily basis. Exposure to arsenic is associated with an increased risk for a 
variety of health problems, such as skin and nerve damage, and cancer. More than 200 
million people worldwide are chronically exposed to drinking water that is contaminated 
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with arsenic that exceeds 10 ppb, the allowable limit of arsenic contaminant level in 
drinking water [6], and suffer from different diseases caused by drinking arsenic-
contaminated water. The major countries that suffer from arsenic contamination are 
Taiwan, Bangladesh, India, and Chile, where the arsenic concentrations in drinking 
water range from 40 µg/L to 2 mg/L [44, 45], which corresponds to 532 nM to 27 µM, 
respectively. In the United States, the maximum arsenic contaminant level in public 
drinking water is 10 ppb. However, approximately 15% of the U.S. population rely on 
private wells for their water supply that were found to have arsenic levels greater than 10 
ppb [46-49]. Ingesting arsenic in naturally contaminated food and water is the most 
common route of arsenic exposure. Unfortunately, it is difficult to obtain an accurate 
measurement of the absorbed dose of arsenic in specific tissues, mainly due to variation 
among individuals [50], including both endogenous and exogenous factors, such as 
gender and occupational exposures, respectively. In 2000, Pi et al. demonstrated the 
average blood arsenic level in people who were exposed to high levels of arsenic in their 
drinking water approximately for 18 years to be about 100 nM [51], which is the 
concentration that we used in this dissertation and from this point forward referred to as 
an ‘environmentally relevant level’ of arsenic. The lethal human adult dose for ingested 
arsenic is about 600 µg/kg/day [1], which is about 60 times higher than the standard set 
by the EPA.  
Arsenic Absorption, Distribution, Metabolism, and Excretion (ADME) 
Ingestion is the main route of environmental arsenic exposure, and arsenic is 
readily absorbed from the gastrointestinal-tract (GI tract). The liver is the main site of 
arsenic metabolism, and historically, methylation steps have been characterized as a 
critical arsenic metabolism process (Fig. 2). This arsenic methylation process was 
initially studied by Frederick Challenger and his colleagues in the 19th century [52, 53]. 
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When arsenate (pentavalent arsenic) enters the cells, it gets rapidly reduced by arsenate 
reductase to arsenite (trivalent arsenic) [54, 55]. Arsenite, then gets methylated by 
arsenic (III) methyltransferase (AS3MT) as it attaches a methyl group. AS3MT uses S-
adenosylmethione (SAM) as the methyl donor to generate the metabolites [56]. Arsenic 
metabolites including monomethylarsonous acid (MMAIII), monomethylarsonic acid  
(MMAV), dimethylarsinic acid (DMAIII), and dimethylarsenic acid (DMAV) are produced 
(Fig. 2).  
There is an alternative model for arsenic methylation that has been proposed by 
Hayakawa et al. that suggests glutathione (GSH) serves as a chaperone during the 
methylation step and the products are trivalent arsenic species [57]. Nonetheless, it is 
important to highlight that humans convert inorganic pentavalent arsenic to MMA 
species, and further into DMA species. Though both pentavalent and trivalent forms of 
arsenic are environmentally relevant, pentavalent arsenic is not readily taken into cells, 
unless the cells are phosphate deprived, as it requires phosphate transporters to enter 
the cells [58]. However, trivalent arsenic is taken into cells much faster than pentavalent, 
as it is imported by aquaporins [58], which can explain lower rate of accumulation of 
pentavalent arsenic species [59-61]. This further suggests higher potency of trivalent 
arsenic over pentavalent.  
The relative distribution of arsenic metabolites in the urine varies among 
population groups, which suggests genetic polymorphism of human methyltransferases 
[62-64], which can then increase the disease susceptibility in people.  A study that was 
done in northern Argentina has shown polymorphisms of AS3MT influencing its activity, 
resulting in variation in the urinary arsenic metabolites as the women in northern 
Argentina had a higher ratio of DMA/MMA [65], which reflects better clearance of arsenic 
from the body, increasing arsenic tolerance [66]. Similarly, another study from Chile has 
shown four polymorphisms of AS3MT that are associated with more efficient arsenic  
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Figure 2. The metabolism pathway of inorganic arsenic.  
The metabolism pathway of arsenate undergoing reduction and methylation to produce 
metabolites in pentavalent and trivalent forms. The products of inorganic arsenic 
metabolism include MMAIII, MMAV, DMAIII and DMAV. Unlike humans, rats can undergo 
another round of methylation from DMAIII to trimethylarsine oxide (TMAO or TMAV). 
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metabolism [67].  However, there are other polymorphisms of AS3MT resulting in a 
higher urinary MMA/DMA ratio that is associated with arsenic-related diseases, such as 
cancer [66]. Because the methylation process is important in elimination of arsenic from 
the systemic circulation, it is easy to assume that methylation is a detoxification process 
of arsenic as it enhances excretion of arsenic from the systemic circulation. However, all 
arsenic metabolites are toxic to different degrees. For example, DMAV, MMAIII and 
DMAIII are observed to be more cytotoxic and genotoxic than arsenite [59, 60, 68, 69]. 
Thus, arsenical metabolites are not just the by-products of inorganic arsenic metabolism; 
they, too, exert toxic effects. 
Target Organs 
Skin 
The skin is the major target organ of arsenic and usually the first manifestation of 
arsenic toxicity [70]. There is a strong association between arsenic exposure and 
dermatological effects, including blackfoot disease, hyperkeratosis and 
hyperpigmentation [71, 72]. Several in vitro studies support the epidemiological studies 
as shown in Table 3.  
Lung 
There is strong evidence that shows association between arsenic and respiratory 
illness, such as bronchitis. Though arsenic can cause non-cancer diseases, non-small 
cell lung cancer is a common consequence from arsenic exposure, especially from 
chronic arsenic exposure. A study by Smith et al. has shown that early life exposure to 
arsenic can lead to pulmonary diseases in adulthood, such as lung cancer, highlighting 
the late effects of early life arsenic exposure [73]. Several studies have shown malignant 
transformation and epithelial-mesenchymal-transition (EMT) in lung cells from chronic 
arsenic exposure shown in Table 4, as well as in in vivo studies [74-78]. Based on 
11	
epidemiological studies, countries, such as Inner Mongolia and Argentina observed a 
positive association between arsenic exposure and lung cancer in both sexes [79, 80]. 
Heart 
There is evidence that show strong association between arsenic exposure and 
development of cardiovascular and coronary artery diseases. Many studies suggest 
arsenic-induced oxidative stress, inflammation, endoplasmic reticulum stress and 
unfolded protein responses play roles in development of cardiovascular diseases [81]. 
Consistently, mice exposed to arsenic for 24 weeks developed lesion formation in the 
aorta [82]. However, many of these studies are established by using high doses (>5 
mg/L) of arsenic exposure [82, 83]. Most of affected populations worldwide suffer from 
chronic exposure of low to moderate level of arsenic and whether low level of arsenic 
exposure leads to cardiovascular diseases still remains inconclusive [81, 84].  
Liver 
As the liver is the main site of arsenic metabolism, it is one of the major target 
organs of arsenic. There is evidence that chronic arsenic exposure causes epigenetic 
changes in the liver that can induce liver disease by increasing inflammatory responses 
[81]. Interestingly, inflammation is an important factor that contributes to cardiovascular 
disease as well, thus there is evidence that endothelial dysfunction can be caused by 
indirect effects on the liver caused by arsenic-induced inflammation. Further, a study has 
shown increased serum levels of liver injury biomarkers can be used to measure 
cardiovascular risk as well [85], suggesting a link between liver disease and 
cardiovascular disease. Chronic arsenic exposure is also known to cause liver cancer, 
but the mechanism still remains elusive. There are several proposed mechanisms, 
including oxidative DNA damage [86-89], impaired DNA repair [90, 91], apoptotic 
tolerance [92], and epigenetic modulation [93-96]. 
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Models for studying Arsenic Toxicity 
Many epidemiological studies show adverse effects from arsenic exposure, 
including carcinogenesis in humans. However, the mechanism by which arsenic induces 
cancer development is still unclear. To elucidate the mechanism and its targets, both in 
vitro and in vivo models are widely used. 
Rodent models of arsenic toxicity 
Rodent models of arsenic toxicity are frequently used, as the target sites of 
arsenic carcinogenic effects in rodents are concordant with most of the human targets of 
arsenic [97]. However using animal models to understand the mode of action for 
inorganic arsenic-induced carcinogenesis still remains controversial [98]. The 
controversy is due to different ADME of arsenic between rodents and humans. Unlike 
humans, rats can metabolize further to trimethylarsine oxide (TMAV) [99], rendering 
rodents to be less sensitive to arsenic toxicity due to rapid clearance [22]. Not only 
species, but also strain differences in rodents, also alter sensitivity to arsenic [100].  
Despite the limitations, the rodent models are widely used and known to reflect 
human toxicological responses. Studies have observed tumorigenesis in mice exposed 
to arsenic in multiple target organs, including lungs [75], which is consistent with 
epidemiological studies [101-107]. Animal studies are also useful in understanding the 
magnitude of toxicity of arsenic species, as different forms of arsenic species have 
preferential target organs. GI tract and kidneys appear to be sensitive target organs for 
MMA, whereas bladder and kidneys are the sensitive target organs for DMA [1]. Further, 
non-cancer diseases can arise from chronic exposure to low levels of arsenic. Based on 
epidemiological studies, the majority of non-cancer disease burden and mortality from 
low level of chronic arsenic exposure is cardiovascular disease and coronary artery 
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disease [108-111], which is consistent with the animal studies [112]. These studies 
suggest that animal studies are useful in assessing adverse effects of arsenic and its 
relevance to human exposure. However, it is important to recognize that the 
pharmacokinetics of arsenic in rodent models limit our understanding of the 
pharmacodynamics of arsenic exposure in humans.  
 
In vitro models of arsenic toxicity  
In vitro models have become a crucial tool for understanding the molecular 
mechanisms underlying arsenic toxicity and carcinogenesis. By using tissue culture 
models, we can more specifically define and refine experimental conditions and 
ultimately perform more focused in vivo experiments and epidemiological studies.  
In vitro models include 2D (two-dimensional) systems, which use cells grown in a 
single layer, and 3D (three-dimensional) systems, that grow cells on a matrix or in 
suspension, to mimic the in vivo architecture, better representing in vivo scenario. 
Nonetheless, both in vitro models are reproducible and cost effective, serving as a 
platform for more in vivo experimental models. However, since in vitro models are static 
systems and look at cells in isolation, they do not simulate the real body condition. Thus, 
ultimately, animal models and epidemiological studies are needed to determine if 
predictions are physiologically relevant. The advantages and disadvantages of in vitro 
and in vivo studies are summarized in Table 2. 
 
Arsenic and Lung Cancer 
i. Arsenic in Drinking Water and Lung Cancer Development 
A common type of cancer in the U.S. that is induced by chronic exposure of 
arsenic is lung cancer [113-115]. The two major forms of lung cancer are non-small cell 
lung carcinoma (NSCLC), and small cell lung carcinoma (SCLC). NSCLC accounts for 
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Table 2: Advantages and disadvantages of in vitro and in vivo studies. 
Primary Cells Immortalized Cells In vivo animal models 
Advantages - Genetically stable 
- Physiologically relevant to in 
vivo 
- Rapid 
- Cost effective 
- Repeatable 
- Not limited lifespan 
- Relevant to effects on 
human 
- Study of complex 
interactions 
Disadvantages - Limited lifespan 
- Limited proliferative capacity 
- More expensive than 
immortalized cell culture 
-Sensitive and easy to get 
contaminated 
- Multiple changes upon 
immortalization 
- Difficult to extend results 
to a whole organism 
- Expensive 
- Time consuming 
- Ethical concerns 
- Difficult to control due 
to variables 
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more than 80% of all lung cancer. NSCLC can be divided into three major histological 
subtypes: squamous-cell carcinoma, adenocarcinoma, and large-cell lung cancer. 
Adenocarcinoma is the most common type of lung cancer in patients who have never 
smoked. Squamous-cell carcinoma is also frequently observed in non-smokers, and is 
highly associated with chronic exposure to arsenic [102, 103]. Previous studies reveal a 
direct correlation between arsenic in drinking water and cancer development [45, 80, 
102, 103, 114, 116-128]. To investigate a direct environmental factor that is associated 
with lung cancer development in individuals who have never smoked, Putila and Guo 
identified a positive correlation between arsenic levels and lung cancer incidence [114]. 
This study underscored the association between arsenic and lung cancer, independent 
of smoking and socioeconomic status in the United States [114]. Particularly, people 
who reside in the Appalachian portion of Kentucky have a higher incidence of lung 
cancer due to coal mining in Appalachia [129], as arsenic is naturally found in rocks and 
coal. This direct relationship between arsenic and lung cancer was also observed in 
countries that have high levels of arsenic in drinking water that can range up to 300 µg/L, 
which approximately corresponds to 4 µM, and these countries had some of the highest 
incidences of lung cancer in the world [123, 128, 130-132]. In Bangladesh, 1 in 16 
cancer deaths are attributable to arsenic exposure in drinking water [133].  
ii. Early Life Exposure to Arsenic and Lung Cancer
Not only post-natal arsenic exposure, but also pre-natal arsenic exposure can 
lead to lung cancer as well. As pre-natal stage is a critical period of development, young 
children in Chile, who had in utero-only and/or early-life arsenic exposure concentrations 
nearly up to 1,000 µg/L, developed lung cancer [73]. Consistently, when pregnant mice 
received 85 ppm arsenic-contaminated water only during pregnancy (gestation days 8 to 
18), the offspring had lung tumor formation in adulthood [134]. These studies highlight 
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the lethality of pre-natal exposure to arsenic, as the placenta cannot serve as a barrier to 
arsenic. A study compared the cancer progression in mice with whole-life 24 ppm 
arsenic exposure (exposure before and after birth and termination months before a full 
life span [135]) and in utero-only 85 ppm arsenic exposure (gestation days 8 to 18), and 
observed development of lung adenocarcinoma and hepatocellular carcinoma in both 
groups of mice with whole-life and in utero-only exposure [136]. However, there were 
higher incidences of cancer development in offspring that had whole-life arsenic 
exposure. These results suggest whole-life arsenic exposure can aggravate the tumor 
progression [75, 137, 138]. 
iii. Effects of Acute and Chronic Arsenic in skin and lungs in in vitro models
As skin and lungs are the two major target organs of arsenic exposure shown by 
previous human and animal studies [2-4, 75], several research studies have used these 
epithelial cell lines for the in vitro analysis of arsenic effects. The most commonly used 
cell lines are HaCaT and BEAS-2B cells, which are immortalized human keratinocytes, 
and bronchial epithelial cells, respectively.  Although studies have reported that they are 
non-malignant [139, 140], their immortality raises concerns for scientists who utilize 
these cell lines to mimic human exposure to arsenic. Thus, there are several studies that 
have used primary or patient-derived cell lines to exhibit normal human physiology and 
biochemistry. However, these cell lines are a challenge in studying chronic arsenic 
exposure due to their limited lifespan. A compilation of these in vitro studies [Tables 3 
(skin) and 4 (lung)] allows us to analyze the findings from studies utilizing a variety of cell 
lines, arsenic concentrations and exposure times. The variations in arsenic 
concentrations make direct comparisons challenging; however, the majority of these 
studies reflect the differences in the level of arsenic exposure across the globe. 
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Table 3: In vitro studies using Skin cells. 




< 18h N/D é Cell proliferation 
éGM-CSF, TGFα, and TGFβ mRNA 
[141] 
NHK 0.001-5 μM 24h N/D é Cell proliferation 
é p53 expression, p53 binding to DNA 
Activation of PI3K/PKB/GSK3β pathway 
[142] 
HaCaT 0.5, 2, 10 μM 24h N/D é AIM2 protein expression [143] 
HaCaT 4 and 8 μM < 24h N/D é Protein and mRNA levels of p62 [144] 
HaCaT 50 μM 24h N/D é CD34 expression [145] 
HaCaT 2.5, 5, 10, 20 
μM 




HaCaT 0.05, 0,1, 0.5, 
1, 5	μM 
24h N/D Changes in hydrogen peroxide, 8-OHdG, 
MDA, and superoxide levels 
[147] 
HaCaT 5, 10, 20, 30, 
40 60 μM 
<24h N/D NRF1 overexpression reduces arsenic-
induced cytotoxicity and apoptosis 
[148] 
HaCaT 2.5, 5, 10, 20 
μM 
24h N/D ê XPA, XPD, and XPF gene expression 
levels, H3K18ac modification 
Induces DNA damage 
[149] 
HaCaT 0 – 40 μM 24h N/D Low dose, generation of ROS, é cell 
survival and m6A and methyltransferases 
High dose, écytotoxicity, oxidative stress, 




HaCaT 2.5 uM 8w Yes PI3K/AKT pathway-dependent Cyclin D1 
expression 
[151] 
HaCaT 0.6 μM* 18w Yes é Colony formation and growth rate 
é CD44v6 expression 
é G2/M and S phases 
é Activating NFkB and p53 genes 
[152] 
HaCaT 500 nM 4w N/D é miRNA 21, 200a and 141 [153] 
HaCaT 1 μM 15w Yes ê let-7 
Activation of Ras/NFkB signaling pathway 
[154] 
HaCaT 0.5, 2, 10 μM 48 and 
72h 
N/D At low concentration- é colony formation 
and proliferation 
At high concentration-ê cell viability, é 
cleaved caspase-1 and AIM2 
inflammasome 
[143] 
HaCaT 100 nM 3 and 7w N/D Arsenite-dependent small RNA and mRNA 
differential expression 
[155] 
HaCaT 100 nM 7w N/D é G2/M phase 
644 miRNA differentially expressed 
[156] 
HaCaT 0.6 μM* 8w N/D é miRNA 21, PTEN, PCDC4 [157] 
HaCaT 0.05 and 0,1 
μM 
15w N/D é Cell proliferation and cell cycle 
progression from G1 to G2/M phase 
é Total Cyclin D1, p-AKT, p-GSK-3b, p-
p21, p-p27 
ê p-Cyclin D1, p21, p27 
[158] 
HaCaT 0.1 and 0.2 
μM 
< 4w Yes é Cell proliferation and TGIF expression, 
invasion 
EMT transition markers alteration, MMP 
activation, invadopodia formation. 
[159] 
HaCaT 100 nM 8w N/D é Structural abnormalities in cells 
overexpressing has-miRNA 186. 
é BUB1 expression 
[160] 
HaCaT 5 μM <72h N/D é ZRANB2 expression 
ZRANB2-directed TRA2B splicing impaired 
Arsenite displaces Zn2+ from ZRANB2 zfms
[161] 
HaCaT 1 μM 12w N/D é p62, Nrf2, HO-1 and SOD expression 
levels 
ê Autophagy by up-regulating mTOR 
[162] 
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* The original study used in ppb
Duration in hours (h), days (d), and weeks (w) 
GM-CSF: Granulocyte-macrophage colony-stimulating factor; TGFα: Transforming growth factor alpha; TGFβ: Transforming 
growth factor beta; PI3K: Phosphoinositide 3-kinase; PKB: Protein kinase B (also known as Akt); AIM2: Absent in melanoma 
2; CD34: XPA: Xeroderma pigmentosum complementation group A; XPD: Xeroderma pigmentosum complementation group 
D; XPF: Xeroderma pigementosum complementation group F; H3K18ac: Histone 3 Lysine 18 acetylation; NFkB: Nuclear 
factor kappa-light-chain-enhancer of activated B cells); let-7: Lethal-7; GSK-3β: Glycogen synthase kinase 3 beta; BUB1: 
Budding uninhibited by benzimidazoles 1; ZRANB2: Zinc finger RANBP2-type containing 2; TRA2B: Transformer 2 beta; 
UVB: Ultraviolet B; MMP: Matrix metallopeptidase; CK: Creatine kinase; Nrf2: Nuclear factor erythroid 2-related factor 2; 
TLR4: Toll ligand receptor 4; CXCR4: C-X-C motif chemokine receptor 4;  
Activation of PI3K/Akt/mTOR pathway, 
induced autophagy deficiency, changes in 
intracellular hydrogen peroxide, superoxide, 
MDA and 4-HNE 
HaCaT 1 μM 20w Yes é m6A level 
m6A mediates migration and apoptosis and 
attenuates p53 activation to mediate 
arsenic- induced transformation 
[163] 
HaCaT 0.05, 0.1 μM 15w N/D é Cell proliferation, cell cycle progression 
from G1 to S/G2M phase, phosphorylation 
of GSK-3β/Cyclin D1, p21 and p27 
[158] 
HaCaT 1 μM 20w Yes é circLRP6 and ZEB1 levels 
Induces the EMT 
[164] 
Chronic HaCaT 100 nM 28w Yes Morphology changes 
Resistant to UVB-induced apoptosis 
é Active MMP-9, keratin-1, 10, involucrin, 
loricrin 
é CK2 expression and nuclear activity 
é Antioxidant level 
ê Nrf2-mediated antioxidant response 
[165] 
HaCaT 100 nM >25w Yes é MMP-9 secretion 
é CK1, 10, 13, 5, 8, 14, 18 and 15, 
involucrin and loricrin 
[166] 
HaCaT  100 nM 28w Yes 26 miRNAs significantly altered [167] 








HaCaT 100 nM 25w Yes Progressive aberrant DNA methylation, 




Table 4: In vitro studies using Lung cells. 
Cell line Arsenic [  ] Duration Transformed? Cell biology Ref. 
Acute 16HBE14o- 0.2-3.8 μM*	 < 24h N/D ê Wound repair 
é MMP9 mRNA and protein expression 
levels as well as activity 
[171] 
BEAS-2B 0.01-10	μM < 5h N/D é EGFR activity, Hb-EGF mRNA level, p-
ERK and cyclin D1 expression 
[172] 
BEAS-2B 1 μM 24h N/D é miRNA 21 expression 
Activation of STAT3 
[173] 
HBE 0.5, 1, 2, 5, 
10 μM 
24h N/D At low level- ERK activation and prevent 
degradation of HIF-2α. 
At high level- JNK activation to prevent 
degradation of HIF-1α. 
[174] 
BEAS-2B 0.5, 1, 2 μM 24h N/D ê miRNA 199a expression [175] 
BEAS-2B 1 μM 24h N/D ê PDCD4  
é Twist1 expression 
[176] 
BEAS-2B 0.25 μM 24h N/D é IL6, IL8, TNFα and GM-CSF production [177] 
HBE 1- 60 μM < 24h N/D ê cell viability  
é Nrf2 signaling pathway 
Oxidative damage 
[178] 
HBE 1- 60 μM < 24h N/D ê Ca2+ homeostasis of ER 
Apoptosis through mitochondrial 
dysfunction, nuclear translocation of NF-
kB 
[179] 
16HBE14o- 0.8 and 3.9 
μM 
24h N/D ê Ca2+ response to wound healing, P2Y- 
and P2X-mediated Ca2+ signaling 








< 4D N/D ê mucin5AC and 5B at both mRNA and 
protein levels 
é gene expressions of GMLM, HO1 and 
NQO1 
Target retinoic acid (RA) signaling 
pathway 
[181] 
LEC 5 μM < 48h N/D é Intracellular oxidant level 
é Heavy subunit of γ-GCS mRNA 
é c-fos and c-jun mRNA, and NFkB DNA 
binding activities 
[182] 
CFBE41o- 1.3-667 nM Up to 4D N/D Activation of E3 ubiquitin ligase to promote 
degradation of CFTR. 
[183] 
HELF 1 μM 15w Yes é miRNA 21 expression 
Activation of ERK and NFkB 
[184] 
16HBE14o- 130 or 330 
nM 
For 4-5w N/D ê Wound repair, ATP-mediated Ca-
signaling, P2Y receptor function and 
molecular expression 
[185] 
HBE 1 μM 15w N/D EMT 
é Twist1 and Bmi1 regulated by HIF-2α 
[174] 
BEAS-2B 1 μM 15w Yes Activation of STAT3 
é miRNA 21 and secretion of IL-6 
[173] 
HELF 1 uM 15w Yes Activation of ERK/NFkB, JNK/c-Jun, and 
Akt. 
é miRNA 21 
ê PDCD4 and SPRY1 protein expression 
[186] 
BEAS-2B 0.25 μM < 16w Yes é IL6 and GM-CSF production [177] 
BEAS-2B 0.1, 0.5, 1 	
μM 
< 16w Yes ê H3K4me3, H3K9me2, HMT activities 
é KDM5A, HDM activities 
[187] 
BEAS-2B 1 μM 15w Yes ê PDCD4 expression 
é Twist1 and miRNA 21 expression levels 
[176] 
HBE 2.5 μM 13w Yes é miRNA 155 expression 
ê NRF2 levels 
[188] 
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* The original study used in ppb or μg/L
Duration in hours (h), days (d), and weeks (w). EGFR: Epidermal growth factor receptor; Hb-EGF: Heparin binding 
epidermal-like growth factor; ERK: Extracellular signal-regulated kinase; STAT3: Signal transducer and activator of 
transcription 3; IL: Interleukin; HIF: Hypoxia-inducible factor; JNK: c-Jun N-terminal kinase; PDCD4: Programmed cell 
death 4; TNFα: Tumor necrosis factor alpha; γ-GCS: Gamma-glutamylcysteine cynthetase; P2Y: Purinergic receptors; 
EMT: Epithelial mesenchymal transition; BMI1: BMI1 polycomb ring finger oncogene; SPRY1: Sprouty1; H3K4me3: 
Histone 3 Lysine 4 trimethylation; H3K9me2: Histone 3 Lysine 9 dimethylation; HMT: Histone methyltransferase; HDM: 
Histone demethylase; KDM5A: Lysine demethylase 5A; PIK1: Phosphatidylinositol 4 kinase PIK1; CCL18: C-C motif 
chemokine ligand 18; CXCL11: C-X-C motif chemokine 11; SATB2: Special AT-rich sequence-binding protein 2; PALA: N-
phosphonacetyl-l-aspartate; Rb: Retinoblastoma; mTOR: mammalian target of rapamycin; p70S6K1: p70-S6 kinase 1; 
COX-2: Cyclooxygenase-2; HMOX1: Heme oxygenase 1; PTEN: Phosphate and tensin; SLC38A3: Solute carrier family 
38 member 3; TGFα: Transforming growth factor alpha 
BEAS-2B 0.1-10 	μM < 48h N/D é mitotic accumulation 
Plk1 activation 
[189] 
BEAS-2B 0.25 μM 12w Yes Macrophage activation 
é IL10, TGFβ, CCL18, IL12 and CXCL11 
secretion 
ê Autophagic activity 
[190] 
BEAS-2B 1.25, 2, 2.5, 
5, 10 μM 
48h and 
6w 
Yes ê miRNA 31 expression 
é SATB2 protein and mRNA levels  
[191] 




Yes Morphological, motile and proliferative 
changes, activation of autophagy 
é EMT via MEK/ERK1/2 signaling 
[192] 
BEAS-2B 0.5 μM 12w Yes é Increased metastatic potential 
ê Metastatic potential of arsenic-
transformed lung epithelial cells from loss 
of SOX9 
[193] 
HBE 2.5	μM 13w Yes é miR- 106b and 18b 
m6A level and its modification controlled by 
its methyltransferases and demethylase 
[194] 
HBE 66.5, 133, 
and 667 nM* 
6D N/A ê Expression of host defense genes, 
lysozyme release and bactericidal activity 
Alters transcriptional responses to 
Pseudomonas aeruginosa 
[195] 




HBE 1 μM 22w Yes é Nrf2-mediated antioxidant levels 
ê ROS and MDA levels 
[197] 
HBE 1 μM 15w N/D é Cell proliferation, STAT3 activation 
Transfer of miR-21 via exosomes 
[198] 
HBE 1 μM 15w Yes é Angiogenesis in vitro and in vivo, VEGF 
expression 
[199] 
HBE 1 μM 15w Yes é Inflammation, IL-6 and IL-8 via HIF-2 α [200] 
16HBE14o- 0.8 and 3.9 
μM 
5D N/D Alters protein and mRNA levels of tight 
junction proteins in airway epithelial cells. 
[201] 
Chronic SAEC 6.7 μM* 24w Yes é Micronuclei incidence, PALA resistant 
characteristics, c-H-ras, c-myc, and c-fos 
protein expression. 
ê WT p53 expression and 
hyperphosphorylated Rb 
[202] 
BEAS-2B 0.25, 1, 5 μM 26w Yes é Cell proliferation 
Activation of AKT, ERK, mTOR and 
p70S6K1 pathways 
[203] 
BEAS-2B 1 μM 26w Yes ê miRNA 99 expression 
é COX-2 and HIF-1α 
[175] 
HPL-1D 2 μM 38w Yes Activation of AKT, ERK 
é Cell proliferation, EMT markers, 
HMOX1 and HIF-1α mRNA levels, MMP2 
activity 
ê PTEN and SLC38A3 mRNA levels 
[78] 
BEAS-2B 0.25 μM 24w Yes é miRNA 301a [204] 
BEAS-2B 100 nM 24w N/D é TGFα protein and mRNA levels, EGFR 
expression and activity 
[42] 
HBE 2 μM < 48h N/D ê Mitochondrial function 
é Glycolytic metabolism, M2 polarization 
of macrophages 
[205] 




The range of concentrations is consistent with the notion that there is no “correct” 
arsenic concentration or consensus in the field. To understand the mechanism of 
arsenic-induced diseases, both acute and chronic arsenic exposures were widely used 
in in vitro studies. Because both skin and lungs are the major target organs from arsenic 
exposure, this dissertation focuses on both acute and chronic arsenic effects on these 
organs. 
Acute arsenic study in vitro 
As discussed in the health effects of arsenic section, acute arsenic exposure 
does not lead to human carcinogenesis. However, in both skin and lung cell lines, acute 
(less than 24 hours) and subacute/subchronic (>24 hours but < 24 weeks) arsenic 
exposures alter several cell cycle regulated genes, particularly Cyclin D1, and 
contributes to increased G2/M phase of cell cycle [152, 156, 158, 172]. Multiple lines of 
evidence show that cell cycle deregulation contributes to the development of cancer 
[207, 208]. Furthermore, arsenic-exposed skin and lung cells have altered miRNA 
expression, mostly from acute and subacute/subchronic exposure. For example, miRNA-
21 is upregulated in both types of cells from arsenic exposure [153, 157, 173, 176]. 
Increased expression of miRNA-21 is found to be a characteristic of cancer cells and 
alters cellular phenotypes, i.e., increased cell proliferation and invasion [209-211]. 
Despite these alterations, acute arsenic exposure does not induce cancer mainly due to 
a short duration of the exposure.  
Chronic arsenic study in vitro 
The chronic arsenic exposure that is associated with carcinogenesis in humans 
can be recapitulated in in vitro studies by exposing either lung or skin cells to arsenic for 
> 24 weeks. Recognizing the need of elucidating arsenic-induced carcinogenesis, 
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investigators have tried to identify the molecular basis for cell transformation and found 
the chronic arsenic treatment leads to an increase in metalloproteinase activity [165, 
166, 168], an increase in invasion and proliferation [78, 168, 203], and alterations in 
gene expression that are involved in cell proliferation [78, 165, 166, 168, 175]. These 
observed data lead to further studies in understanding the mechanism of arsenic-
induced transformation, as the clear mechanism of arsenic-induced carcinogenesis still 
remains elusive.  
Interestingly, in skin cells, chronic arsenic exposure increased secretion of matrix 
metallopeptidases (MMP) and creatine kinases (CK) [165, 166, 168]. Particularly MMP9 
has a role in remodeling extracellular matrix and cell surface protein cleavage. Its 
increased expression and activity are widely associated with cancer development [212]. 
Several population studies have shown increased MMP9 levels in individuals who 
ingested arsenic-containing drinking water at least for one year [213-216], which renders 
MMP9 as a strong prognostic marker for arsenic-induced cancer, as well as a possible 
driver of arsenic-induced carcinogenesis. Thus, in vitro studies can serve as reliable 
tools that reflect human exposure to arsenic. 
Additionally, it is also important to note that the effects from chronic arsenic 
exposure may or may not occur under conditions of an acute exposure. Therefore, it is 
critical to have proper controls and identify the endpoint of each study to generate the 
most biologically meaningful in vitro studies. 
iv. Proposed Mechanisms of Arsenic-induced Carcinogenesis
Proposed mechanisms of arsenic-induced carcinogenesis include oxidative 
stress [217-223], epigenetic changes including histone modification, miRNA expression, 
DNA methylation [93, 224-234], aneuploidy [235], and activation of oncogenic pathways 
[172, 236-253], such as the epidermal growth factor receptor (EGFR). The EGFR is a 
well- established biomarker of cancer [254-257], and studies have found that the EGFR 
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is overexpressed in a variety of tumors and cancer cells, which correlates with poor 
patient prognosis [258-273], including NSCLC [274-276]. Both previous studies and our 
studies have shown acute arsenic exposure induces overexpression of EGFR in human 
bronchial epithelial cells [277] (Fig. 3). Despite a direct association between 
supraphysiological levels of arsenic and lung cancer, how chronic exposure to “a 




i. Structure and Activation of EGFR 
EGFR is a receptor tyrosine kinase (RTK) localized on the cell surface (Fig. 4). 
As one of the ErbB family receptors (EGFR, ErbB2, ErbB3, and ErbB4), EGFR is 
activated by specific ligands, and there are 7 endogenous EGFR ligands (epidermal 
growth factor (EGF), transforming growth factor-α (TGFα), heparin binding epidermal 
growth factor (HB-EGF), amphiregulin (AREG), betacellulin (BTC), epigen (EPGN), 
epiregulin (EREG)). Of these ligands, HB-EGF and BTC are known to have a high 
affinity for the receptor and have robust signaling [278-280]. The EGFR and the other 
ErbB family members can be divided into three main domains: extracellular domain, 
transmembrane domain, and intracellular domain, which consists of a kinase domain 
and tyrosine residues on the C terminus that serve as docking sites for many 
downstream proteins. Ligand binding to the extracellular domain of the EGFR leads to a 
conformational change that allows receptor dimerization and activation of the intrinsic 
kinase activity. Once activated, the kinase from one receptor trans-phosphorylates 
tyrosine residues on the intracellular carboxy-terminus of its receptor pair (Fig. 4). These 
newly formed phosphotyrosines then serve as docking sites for downstream signaling  
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Figure 3. Acute arsenite induces overexpression of EGFR.  
Immunblot of EGFR and phosphotyrosine 1068 (pY1068) in Beas-2B cells treated with 
arsenite at the indicated concentrations for 24 hours. 10 ng/mL of EGF treatment in 
Beas-2B cells was used as a positive control. EGF was stimulated after 2 hours of 
serum-starvation, and it was stimulated for 7 minutes. The samples were resolved on 
7.5% SDS-PAGE.  
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Figure 4. EGFR structure.  
When the receptor is not occupied by a ligand, the cysteine-rich regions of the 
extracellular domain of the receptor interact with each other and maintain a “closed” 
conformation. When a ligand binds to the ligand binding domains of the extracellular 
domain, the EGFR undergoes a conformational change, exposing cysteine-rich regions. 
These regions, then, interact with other exposed cysteine-rich regions of another ErbB 
family receptor. This allows receptor dimerization and activation of the intrinsic kinase 
activity. Once activated, the intracellular kinase from one receptor trans-phosphorylates 
tyrosine residues on its receptor pair. These newly formed phosphotyrosines then serve 
as docking sites for downstream signaling proteins that mediate cell proliferation, 
survival, tumorigenesis, and differentiation. Red=ligand; green=cysteine-rich regions; 
blue=ligand-binding domains; purple=inactive kinase domains; yellow=active kinase 
domains.  
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proteins (effectors) that mediate cell proliferation, survival, tumorigenesis, and 
differentiation. 
ii. EGFR Function in Embryonic Development
The EGFR is a critical component in development. EGFR expression was 
observed in embryogenesis, and its ligands, specifically EGF and TGFα, were also 
expressed from 4- to 8-cell stage of embryogenesis [281-286]. The co-localization of the 
ligands with the EGFR throughout the critical stages of embryogenesis underscores the 
requirement of full activation of EGFR for proper development. Therefore, EGFR null 
and/or EGFR mutations are deleterious. Earlier studies have found EGFR null mice were 
either embryonically lethal or died shortly after birth [287]. The mice that had EGFR 
mutation manifested changes in hair and skin, which support the roles of EGFR in 
epithelial development [288, 289].  
iii. The Endocytic Trafficking Pathway of EGFR
When a ligand binds to the EGFR, the activated EGFR gets internalized via 
clathrin-coated pits into the cell. Once the clathrin is shed, the vesicle then fuses with the 
early endosomes [290]. From the early endosomes, the receptors can have two different 
fates; the receptors can move back to the plasma membrane from the early endosomes 
(recycling), or the receptors can be degraded via lysosomes. For receptors to degrade, 
the receptors-containing early endosomes increase acidity to “mature” into the late 
endosomes [291]. The late endosomes then fuse with lysosomes to degrade the 
receptors (Fig. 5). The degradation of EGFR is tightly regulated to control the 
downstream signaling events, such as proliferation. Thus, improper regulation of 
degradation of EGFR can lead to overstimulation of proliferative signaling and contribute 
to cancer development. When the receptors are activated, the tyrosine residues of the  
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Figure 5. The endocytic trafficking pathway of EGFR.  
When a ligand binds to the receptor, the receptors become activated. The activated 
tyrosine kinase domains then induce trans-phosphorylation of the tyrosine residues on 
the carboxy-terminus of its receptor pair. This phosphorylation triggers c-Cbl to be 
recruited to the activated receptors and ubiquitinates the receptors. The activated 
receptors get internalized via clathrin-coated pits into the cell. Once the clathrin is shed, 
the vesicle then fuses with the early endosomes. From the early endosomes, the 
receptors can have two different fates; the receptors can move back to the plasma 
membrane from the early endosomes (recycling), or the receptors can be degraded via 
lysosome.  
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kinase domain of the receptors get phosphorylated and get internalized into the cell. This 
receptor activation triggers c-Cbl, which is an E3 ubiquitin ligase, to be recruited and 
binds to a specific phosphorylated tyrosine residue (pY1045) of the kinase domain of the 
receptor [292]. This binding causes ubiquitination of the receptors and the receptors get 
marked for degradation via lysosomes [293, 294]. As mentioned earlier, the other fate of 
the internalized receptors is to recycle back to the plasma membrane. Previous studies 
have found even without any ligand stimulation, about 10% of the EGFR constitutively 
internalize and recycle back to the plasma membrane [295], predominantly by the basal 
expression of TGFα, an EGFR ligand that is involved in the recycling of the receptors 
[296]. EGF, on the other hand, is a well-known EGFR ligand, and EGF-stimulated EGFR 
undergo degradation. The different effects between TGFα and EGF ligands are mainly 
due to their sensitivity to the acidic environment [297]. TGFα is pH sensitive, and it is 
known to dissociate from the receptors at pH of about 6.8, whereas EGF is dissociated 
from the receptors at pH of about 5.8 [298-300]. Thus, TGFα gets dissociated from the 
early endosome compartment (pH of about 6.8), which allows the EGFR to recycle back 
to the plasma membrane, whereas EGF:EGFR complex endure the acidic environment 
until they get degraded [300]. The ErbB2 expression levels also affect the recycling 
pathway of the receptors. Studies have observed decrease in EGF-stimulated EGFR 
degradation in cells that overexpress ErbB2 [301, 302]. Further studies supported these 
observations by demonstrating ErbB2 overexpression preventing clathrin-mediated 
endocytosis of EGFR [301, 303]. However, a clear mechanism for ErbB2-induced 
impairment of EGFR endocytosis remains elusive.  
EGFR and Cancer 
There are four main events that can perturb the EGFR regulatory mechanisms, 
which all contribute to cancer development: 1) overexpression of EGFR,  
29	
2) overproduction of its ligands, 3) improper receptor trafficking, and 4) the EGFR kinase
domain mutations. 
i. Overexpression of EGFR
The overexpression of EGFR (as compared to adjacent non-cancerous tissue) is 
seen in many cancers, including colorectal cancer, pancreatic cancer, NSCLC [276, 304-
310], and gliomas [311-316], and is associated with a poor prognosis. Under 
pathological conditions, such as cancer, the normal regulatory mechanisms of the 
signaling pathways are perturbed, resulting in hyperactivation of the signaling pathways. 
The overexpression of EGFR and its association with a poor prognosis can be explained 
by increased sites for the ligands to bind to the receptors, leading to enhanced 
downstream signaling events, such as proliferation.  
ii. Overproduction of the EGFR Ligands
An increase in synthesis of ligands above the basal levels also triggers 
enhancement of the EGFR-induced activation of proliferative pathways. High levels of 
EGFR ligands, including EGF, TGFα, AREG, and BTC, were observed in cancers [317, 
318]. The frequency of overexpression of EGFR and TGFα, has been observed in 
NSCLC patients, and predicts a poor outcome [305]. All ligands function similarly to 
EGF; they bind to the ligand binding domain of the receptors, and induce a 
conformational change in the receptors that leads to dimerization of the receptors and 
increased tyrosine kinase activity. However, their tissue distribution, expression 
regulation, and binding affinity and preferences on the receptors differ from one another, 
all of which can alter EGFR signaling by changing the endocytic trafficking itinerary [319-
323]. 
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iii. Improper Receptor Trafficking
Disruption of proper EGFR trafficking is known to contribute to cancer  
development [324-331] mainly due to poor downregulation of the receptors and 
sustained downstream proliferative signaling. Without any ligand stimulation, the 
unstimulated receptors predominantly localize on the surface of the cells. However, 
when the cells are stimulated with ligand, such as EGF, the internalized receptor co-
localizes with the early endosomes within 10 minutes post-stimulation [332]. Over time, 
the EGF-stimulated cells will have reduced staining of the EGFR in the early endosome 
compartment, due to its lysosomal degradation. However, when the EGFR endocytic 
trafficking pathway is perturbed, specifically between the early and the late endosomes, 
the EGFR will remain in the early endosome compartment and still active, prolonging the 
signaling as the EGFR accumulate in the early endosome compartment [333]. A 
previous study observed an increase in the EGFR protein expression level in response 
to prevention of the EGFR degradation [328], which suggests improper EGFR endocytic 
trafficking can contribute to both overexpression and hyperactivation of EGFR, leading to 
carcinogenesis. Thus, abnormalities in the endocytic trafficking of signaling receptors are 
now well-established hallmarks of malignant cells [334, 335].  
iv. Kinase Domain Mutations.
Not only overexpression of the wild type EGFR, but also expression of the 
mutant EGFR kinase domain can contribute to cancer development. The most common 
EGFR kinase domain mutation is EGFRvIII, which is a deletion of residues 6 to 273. 
Despite the inability to bind to the ligands, EGFRvIII is known to induce constitutive 
activation and trigger downstream signaling [336]. This form of receptor is known to 
enhance tumorigenesis, proliferation, and metastasis of tumors [337-340]. Such 
mutation is commonly observed in about 40% of glioblastoma cases [341-343]. Even 
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though the overexpression of EGFR is commonly observed in NSCLC cases, there are 
only about 10 to 30% of NSCLC patients who are EGFR mutant positive [344]. The most 
common EGFR kinase domain mutations in NSCLC patients are exon 19 deletion, which 
is near the ATP-binding pocket that tyrosine kinase inhibitor (TKI) targets, and a 
mutation in exon 21 by substituting leucine 858 with arginine, or L858R [336, 345]. 
These kinase mutations cause constitutive activation of the EGFR by destabilizing the 
inactive conformation of EGFR [346, 347]. Therefore, NSCLC patients with the EGFR 
kinase domain mutations have better clinical response to TKI, as the mutants are more 
sensitive to TKI than the wild type EGFR [348, 349]. Unfortunately, patients with mutant 
EGFR kinase domain acquire resistance to the TKI therapy. A common EGFR kinase 
domain mutation that leads to resistance is T790M (substitution of threonine 790 with 
methionine). The location of T790 is significant, as it is located in the ATP binding pocket 
[350]. This substitution allows structural conformation of the receptors to gain near wild 
type levels of ATP affinity and allow ATP to bind to the kinase domain with higher affinity 
than the drug [350, 351], which supports T790M-induced resistance to TKI. Additionally, 
Shtiegman et al. observed decrease in endocytosis and downregulation of L858R- and 
T790M-containing EGFR, and continuous phosphorylation status of the receptors 
several hours following EGF stimulation, unlike the wild type receptors [326], which 
suggests prolonged downstream signaling and predisposition to lung cancer. 
Particularly, L858R-containing EGFR mutant had impaired recruitment and 
phosphorylation of c-Cbl with EGF stimulation [326].  
v. EGFR-targeted Chemotherapy
Because of the importance of EGFR in cancer development, there have been 
several chemotherapeutic agents that target EGFR. The EGFR-targeting 
chemotherapeutic agents can be divided into two main classes: monoclonal antibodies 
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and small molecule kinase inhibitor. An example of the monoclonal antibody is 
Cetuximab, which targets the extracellular domain of the receptor to prevent 
ligand:receptor interactions. This drug is approved for treatment of cancers, such as 
colorectal cancer and squamous cell carcinoma of the head and neck (NCI, 2018). 
Erlotinib and getfitnib are examples of TKI, which bind to the kinase domain of the 
receptor to prevent activation of the downstream proteins and their signaling. Erlotinib is 
widely used as first-line therapy to treat particularly NSCLC patients [352]. As mentioned 
earlier, patients with mutant EGFR, such as L858R, have good responses to TKI, as 
they induce constitutive activation of the kinase, and such activity is found to increase 
sensitivity to the drug [348, 349, 353]. These specific mutations have higher affinity for 
TKI than does the wild type EGFR, and they have lower affinity for ATP, as compared to 
the TKI [346, 354]. Consistently, NSCLC cells with the mutant EGFR kinase domain 
have lower IC50 value of TKI, as compared to the wild type EGFR [355]. Furthermore, 
TKI inhibited both EGFR activation and proliferation, and induced apoptosis in NSCLC 
cells with the mutant EGFR kinase domain, but it did not induce apoptosis in NSCLC 
cells with the wild type EGFR [348, 356, 357]. Interestingly, when the ErbB2 expression 
was blocked by monoclonal antibodies, enhancement of the mutant receptors’ 
downregulation was observed [326], which highlights the importance of ErbB2 
regulation. Thus, these studies suggest the complexity of the mutant receptors, and 
more specific targets-driven chemotherapeutic agents are needed. There are several 
irreversible inhibitors that target these mutations, and they act through covalent binding, 
but they are yet to be approved [350]. 
EGFR and Arsenic-induced Carcinogenesis 
As mentioned above, both previous studies and our data have shown that acute 
high levels of arsenite exposure induce the overexpression of EGFR in human bronchial 
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epithelial cells [277] (Fig. 3). Understanding the molecular mechanism of such 
phenomena will contribute to developing new drug targets. This dissertation examines 
the effect of an environmentally relevant level of arsenite on the EGFR signaling. 
Arsenic readily accumulates in epithelial cells as they have high content of thiol 
groups, and EGFR plays a critical role in epithelial development. The interaction 
between arsenic and thiol groups supports the role of arsenic in lung cancer 
development through EGFR signaling axis in epithelial cells. In this dissertation, I 
suggest a potential role of chronic arsenite exposure in the regulation of components of 
the EGFR signaling axis. A previous study used micromolar ranges of arsenite, and 
observed increased level of EGFR ligand mRNAs, specifically HB-EGF [172]. HB-EGF is 
seen in a variety of cancers, such as colorectal, cervical, breast and gastric cancers 
[358-362]. Consistently, an earlier study demonstrated increase in TGFα mRNA 
expression levels in mice chronically exposed to arsenic-contaminated drinking water 
[363]. Also, overexpression of TGFα was observed in the tumor from nearly 50% of 
primary NSCLC patients [305]. As mentioned earlier, TGFα is an EGFR ligand that is 
involved in the constitutive recycling of EGFR, which can delay the EGFR lysosomal 
degradation [296], resulting in overexpression of the receptors. Thus, these studies 
support the hypothesis that arsenic has an impact on regulation of the ligands, resulting 
in overexpression of the EGFR. 
There is a scant amount of studies that observe the effect on the receptor 
trafficking upon chronic toxicant exposure. A study has shown arsenic increases protein 
levels of Rab4, a protein involved in the recycling of EGFR [364]. This study suggests a 
potential role of arsenic in altering the endocytic trafficking of EGFR. Under normal 
conditions, EGFR internalizes via clathrin-mediated endocytosis, but at high doses of 
EGF, the EGFR undergoes clathrin-independent endocytosis, including caveolin-
mediated endocytosis [365]. This interplay between clathrin-mediated endocytosis and 
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caveolin-mediated endocytosis controls the expression of EGFR in the cells to prevent 
overstimulation, as caveolin-mediated endocytosis preferentially couples to the EGFR 
degradation [366]. In our study, we observed overexpression of EGFR in response to 
chronic arsenic exposure (Fig. 7), suggesting a possible role of arsenic in dysregulating 
the interplay between the two distinct endocytic trafficking pathways, which contributes 
to arsenic-induced carcinogenesis by allowing overstimulation of EGFR signaling. 
Additionally, acute high levels of arsenic exposure is known to prevent microtubule 
disassembly by losing the integrity of the tubulins and mircotubules [367], and 
microtubules are critical components in movement of proteins between the organelles 
[368]. Thus, the EGFR endocytic trafficking pathway is a potential target site of chronic 
arsenic to induce overexpression of EGFR in the cells. Disruption of proper EGFR 
trafficking is known to contribute to cancer development, such as lung, pancreatic, and 
breast cancers [326, 328, 369]. Despite the importance of proper EGFR trafficking in 
cancer development, there has been no study that tested alterations in the route of 
EGFR trafficking from chronic arsenic exposure.  
Significance and Statement of Specific Aims 
Arsenic is ubiquitous; it can be found in water, air, and food. More than 200 
million people worldwide are chronically exposed to arsenic [6]. These areas include 
Bangladesh, Chile, Mexico, and approximately 1% of the U.S. population, who rely on 
private wells for their water supply (US EPA, 2012a, 2012b) that have arsenic levels 
greater than 10 ppb [46-48, 370]. There is a direct correlation between arsenic in 
drinking water and cancer development [45, 80, 102, 103, 116-128], including non-small 
cell lung cancer (NSCLC). Proposed mechanisms of arsenic carcinogenicity include 
epigenetic [93, 224-226, 229, 230, 232], oxidative stress [217-223, 364, 371, 372], 
alteration in miRNA expression [153, 157, 173, 176, 188, 225, 228, 229, 236, 373-379], 
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aneuploidy [235], and activation of oncogenic pathways [172, 237-242, 244-246, 249, 
250, 252, 253, 377]. However, a clear arsenic-induced carcinogenic mechanism still 
remains elusive. To elucidate the carcinogenic mechanism, we are focusing on an 
established prognostic marker of cancer, EGFR [254-257]. The EGFR is overexpressed 
in a variety of tumors and cancer cells, and is commonly observed in NSCLC [274-276]. 
Both previous studies and our data (Fig. 1) show that acute arsenic exposure (1-10 µM) 
induces overexpression of the EGFR [237, 277]. However, how chronic arsenic 
exposure affects the EGFR expression and its signaling axis remain elusive.  
My research goal was to understand how chronic arsenic exposure disrupts the 
EGFR signaling axis, contributing to overexpression of EGFR, and to develop strategies 
to mitigate the effect of arsenic toxicity. This aligns with the National Institute of 
Environmental Health Sciences’ mission of discovering the impact of environmental 
toxicants on people to promote healthier lives. My hypothesis was that chronic arsenic 
exposure changes the EGFR signaling axis, which contributes to EGFR overexpression. 
The long-term goals were not only to identify novel roles of chronic arsenic exposure in 
the EGFR endocytic trafficking, but also to identify the key driver of chronic arsenic-
induced increased cell migration that may contribute to developing a novel therapeutic 
target of lung cancer. My research was achieved by using BEAS-2B cells, which are 
non-malignant human lung bronchus epithelial cells generated by SV40 transfection 
[380]. They have been widely used to study heavy metal-induced carcinogenesis [381-
385], and they are commonly used in arsenic studies because the lungs are known to be 
one of the major target organs of inorganic arsenic carcinogenesis [113, 175].  
 My hypothesis was tested with the following aims: 
Aim 1: Measure the impact of acute and chronic arsenic exposure on the 
expression levels of the EGFR and its ligands. 
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In order to achieve this aim, we performed western blots, RT-qPCR and ELISA. The goal 
of this aim was to determine the expression differences in EGFR as well as its ligands 
between untreated and arsenic treated cells and it is discussed specifically in chapter 2. 
Aim 2: Determine the route and kinetics of the EGFR trafficking in arsenic-treated 
cells. 
We used flow cytometry to measure the cell surface. The goal of this aim was to 
determine the localization of EGFR in response to arsenic exposure and it is discussed 
specifically in chapter 2. 
Aim 3: Assess EGFR dependency in chronic arsenic-induced increased cell 
migration. 
We used time-lapse microscopy to obtain live-cell imaging and measure effects of 
chronic arsenic exposure in cell speed, persistence and cell protrusion length. Chronic 
arsenic impact on cell migratory ability is discussed specifically in chapter 3. 
The goal of this work was to provide a mechanism by which chronic arsenic acts 
on the EGFR signaling, which will lead to discovering novel therapeutic targets of 
NSCLC. The work proposed in Aim 1 and 2 gave us a biochemical effect of chronic 
arsenic exposure on the EGFR signaling axis and differentiated the impact of acute and 
chronic arsenic exposure in lung epithelial cells. More specifically, we discovered that 
chronic arsenic exposure increases cell surface level of EGFR supported by increased 
TGFα secretion. This work is discussed in Chapter 2 of this dissertation and has been 
published in Toxicology In Vitro in 2020. The work proposed in Aim 3 helped us to 
elucidate EGFR dependency in chronic arsenic-induced increased cell migration that 
may contribute to identifying a novel therapeutic target for lung cancer. This work is 
discussed in Chapter 3 of this dissertation.  
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CHAPTER 2 
CHRONIC AND ACUTE ARSENIC EXPOSURE ENHANCE EGFR EXPRESSION VIA 
DISTINCT MOLECULAR MECHANISMS 
Introduction 
 Arsenic is ranked number one on the ATSDR Substance Priority List (ATSDR, 
2017), and was classified as a group I “carcinogenic to humans” by the IARC in 1973 
based on epidemiological carcinogenicity evidence in humans and in animal models [2-
4]. Arsenic is ubiquitous in the environment and, depending on the dose and duration of 
exposure, can target many different types of tissues and organs, causing a wide array of 
adverse health effects, including vomiting, diarrhea, and cancer [43]. 
The lungs are one of the major target organs of arsenic [75, 175] as 
demonstrated in studies using female mice exposed to arsenic in utero or whole-life 
exposure [75], and supported by epidemiologic studies of children exposed to arsenic 
contaminated drinking water [73, 386]. Countries that have high levels of arsenic in 
drinking water have some of the highest incidence of lung cancer in the world [123, 128, 
130-132]. In particular, adenocarcinoma and squamous-cell carcinoma are the most 
prevalent among people with chronic arsenic exposure [102, 103]. Despite these 
associations, there are no clearly defined mechanisms by which chronic arsenic 
exposure induces carcinogenesis. 
The epidermal growth factor receptor, EGFR is a cell surface receptor tyrosine 
kinase (RTK) that has important roles in developmental biology, tissue homeostasis and 
wound healing.  Overexpression and hyperactivation of EGFR family members (i.e. 
EGFR, ErbB2, ErbB3, and ErbB4) have been well-characterized as biomarkers of a 
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variety of cancers and are associated with poor patient prognosis [265, 309, 387-393]. 
Specifically, the overexpression and hyperactivation of the EGFR (as compared to 
adjacent non-cancerous tissue) is seen in up to 89% of NSCLC [276, 304, 305, 307, 
309, 310, 394, 395]. Given the association of ErbB family of RTKs with cancer, it is a 
logical candidate to link arsenic exposure and lung cancer. 
Binding of one of seven endogenous ligands to the extracellular domain of the 
receptor leads to conformational changes that culminate in receptor dimerization and 
activation of the intrinsic kinase domain [396-398]. Once activated, the kinase from one 
receptor trans-phosphorylates tyrosine residues on the intracellular carboxy-terminus of 
its receptor pair. These phosphotyrosines are docking sites for downstream signaling 
proteins (effectors) that enhance cell proliferation, survival, tumorigenesis, and 
differentiation. Overexpression of the EGFR is commonly the result of one of four 
mechanisms: 1) increased transcription of the EGFR gene, 2) overproduction of its 
ligands, 3) slowed lysosomal degradation of the receptor, and 4) constitutively active 
mutations in the kinase domain. These events increase receptor tyrosine 
phosphorylation and enhance downstream signaling.  
We hypothesized that chronic arsenic exposure modulates EGFR signaling axis 
by causing hyperactivation and overexpression of EGFR in lung epithelial cells, which 
can potentially contribute to lung carcinogenesis. This is supported by report that acute 
arsenite exposure (5-15 µM for 24 hours) increases EGFR expression in HeLa cells 
[277]. However, this level and duration of exposure and cell line do not accurately reflect 
what is observed in epidemiological studies. Thus, we examined the effects of acute 
versus chronic, and used an environmentally relevant level of arsenite exposure on 
BEAS-2B cells, non-malignant human lung bronchus epithelial cells immortalized by 
SV40 transfection [380]. BEAS-2B cells have proven to be an excellent model for 
studying arsenic-induced lung cell carcinogenesis [203, 381]. BEAS-2B cells were 
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exposed to an arsenite concentration of 100 nM, which is the observed arsenic 
concentration in the plasma of individuals that chronically consumed arsenic-
contaminated drinking water, for 24 weeks. 
 
Materials and methods 
 
Cell culture 
Human bronchial epithelial (Beas-2B) cells from American Type Culture Collection 
(Manassas, VA) were grown in growth media [LHC-9 media (Gibco)] on a matrix of 
fibronectin (10 µg/mL) and collagen (35 µg/mL) (FNC Coating Mix, AthenaES). Both 
acute and chronic conditions were grown on FNC coated plates. Chronic arsenite 
exposed cells were treated with 100 nM sodium arsenite (final concentration) (CAS 
7784-465-Fisher Scientific). Three cultures of each condition (0 or 100 nM sodieum 
arsenite) were maintained separately for 24 weeks. Cells were propagated by 
trypsinization and plating at 1 x 106 cells/ 10 cm dish every 3-4 days. Each week 1 x 106 
cells/vial were frozen and stored in liquid nitrogen. The identity of untreated and sodium 
arsenite treated BEAS-2B cells was ensured by STR mapping after completion of 24 
weeks in all three biological replicates (American Type Culture Collection, Manassas, 
VA). In experiments in which the cells were acutely exposed to 3 and 5 µM of sodium 
arsenite for 24 h, cells were grown in BEGM (Bronchial Epithelial Growth Medium) 
medium bulletkit (Lonza) without GA-1000 and EGF. This allowed for the selective 
removal of EGF while preserving the other media components necessary for cell 
viability. Cell morphology was examined under a light microscope (TE-2000; Nikon, 
Tokyo, Japan) with a 4x objective.  
 
Cell lysate preparation 
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When indicated, cells were serum-starved by washing twice with phosphate-buffered 
saline (PBS) in pH 7.3 and incubating in BEGM medium bulletkit (Lonza) without GA-
1000 and EGF. To harvest, cells were washed with PBS, incubated in 5 mM EDTA/PBS 
solution for 15 min at 37 °C to dissociate the cells. Then the cells were counted using 
hemocytometer to ensure equivalent number of cells to be loaded on the gel. The cells 
were equilibrated to 4 °C by incubation on ice and harvested in ice cold RIPA buffer [150 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 10mM sodium 
pyrophosphate, 100 mM sodium fluoride, 50 mM Tris-HCl (pH 8.0)] containing protease 
inhibitor, PMSF (EMD Millipore)]. Cells were solubilized by end-over-end rotation at 4 °C. 
Insoluble material was removed by centrifugation at 21, 130 xg for 10 min at 4 °C. 
Immunoblotting 
SDS sample buffer containing 10% βME was added to the cell lysates and heated at 
95°C for 3 min. Equivalent amounts of sample were separated by 7.5% SDS-PAGE and 
electroblotted onto a nitrocellulose membrane. Membranes were immunoblotted with the 
following antibodies according to the manufacturer’s directions: EGFR (1:1000 in 
5%milk/TBST; Santa Cruz, sc-03), pY1068 (1:500 in 5% milk in TBST; Cell Signaling, 
2234), and α-tubulin (1:5000 dilution in 5%milk; Sigma-Aldrich, T6199). Immunoreactive 
proteins were visualized by incubation with the appropriate horseradish peroxidase-
conjugated secondary antibody (anti-mouse or anti-rabbit, Thermo Fisher) and 
enhanced chemiluminescence (ECL). Images were captured using a Fotodyne imaging 
system (Hartland, WI). Immunoreactive bands were quantified using ImageJ software 
[399]. 
Alamar Blue assay 
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BEAS-2B cells were grown in LHC-9 media in 96-well microplates (10,000 cells/well) for 
24 h. Cells were treated with varying concentrations of arsenic for 24 h, and serum-free 
medium was used as a control. Cell viability was determined using Alamar Blue Reagent 
(Bio-Rad) according to the manufacturer’s directions. Cell-associated fluorescence was 
measured in Gen5 BioTek plate reader (excitation: 530 nm; emission: 590nm). 
RT-qPCR 
RNA was isolated from BEAS-2B cells by using RNAqueous-Micro Total RNA Isolation 
Kit (Thermo Fisher, AM1931). cDNA was synthesized using High-Capacity cDNA 
Reverse Transcription Kits (Thermo Fisher, 4368814). qPCR was performed using 
TaqMan Gene Expression Master Mix (Thermo Fisher, 4369016). The following primers 
were obtained from Thermo Fisher and previously validated: EGFR (Catalog# 4331182, 
Assay ID Hs01076089), ErbB2 (Catalog# 4331182, Assay ID Hs01001580_m1), EGF 
(Catalog# 4331182, Assay ID Hs01099990_m1), AREG (Catalog# 4331182, Assay ID 
Hs00950669_m1), BTC (Catalog# 4331182, Assay ID Hs00156140_m1), and TGFα 
(Catalog# 4331182, Assay ID Hs00608187_m1). The 96-well plate (Thermo Fisher, 
4346906) was read using a StepOnePlus System (ThermoFisher, 4376600). GAPDH 
was used as a normalization control. 
Flow Cytometry 
BEAS-2B cells were dissociated with TrypLE Select Enzyme (Invitrogen) and 
resuspended at a density of 1x106 cells/ml in growth medium. After washes with PBS, 
the cells were stained with phycoerythrin-conjugated anti-EGFR (BD, #555997) for 30 
minutes at room temperature, and flow cytometric analysis was performed using a BD 
FACSCalibur. Data analysis was performed with FlowJo (Tree Star).  
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ELISA 
The 96-well TGFα Microplates (abcam 100646) were coated overnight at 4°C with gentle 
shaking with 100 µL of cell culture supernatants (from 2 ml of a 80% confluent 60 mm 
dish) resuspended in 1X Assay Diluent B. The plates were washed by filling each well 
with 1X Wash Solution using a 96-well plate auto-washer. The plates were then 
incubated with 100 µL of 1X Biotinylated TGFα Detection Antibody for 1 hour at room 
temperature with gentle shaking. After the wash, the plates were then incubated with 
100 µL of 1X HRP-Streptavidin solution for 45 minutes at room temperature with gentle 
shaking. After washing, the plates were incubated with 100 µL of tetramethylbenzidine 
(TMB) One-Step Substrate Reagent for 30 minutes at room temperature in the dark with 
gentle shaking. The ELISA Stop Solution was added and the absorbance was read at 
450 nm. Using the standard curve, the concentrations of TGFα were calculated. 
Transwell assay 
The 8-µm polycarbonate membrane, 6.5-mm inserts (Corning, Inc., Corning, NY) were 
moisturized with serum-free media for 30 minutes at 37°C. After incubation, serum-free 
media containing the indicated concentrations of EGF and arsenic were added in the 
lower chamber. Media from BEAS-2B cells grown in 100 nM sodium arsenite for 24 
weeks (conditioned media) was harvested after 24 hours at 37°C in 5% CO2. A density 
of 100,000 BEAS-2B cells were plated in the upper chamber of the insert (The cells were 
harvested as described above). The cells were allowed to migrate for 16 hours at 37°C 
in 5% CO2. Migrated cells were then fixed in methanol, stained in Giemsa (3250-4, Ricca 
Chemical, Arlington, Texas), and counted under a microscope (TE-2000; Nikon, Tokyo, 
Japan) with a 20x objective. 
Data Analysis 
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Data were analyzed using Graphpad Prism 5.0 Software (Graphpad Software). 
Statistical tests are indicated in the figure legends. 
Results 
Chronic arsenite exposure increases EGFR expression and activity without altering cell 
morphology or viability 
It has been previously demonstrated that HeLa cells acutely exposed to 5-15 µM 
arsenite increase EGFR protein expression [277]. To determine whether this was true in 
human lung epithelial cells (BEAS-2B cells), we repeated this experiment and found 
acute arsenite exposure (5 µM for 24 hours) caused a 1.5-fold increase in EGFR levels, 
but did not stimulate EGFR activity measured by pY1068 level (Fig. 6A). Additionally, we 
noted that acute arsenite exposure is accompanied by a decrease in cell viability and 
morphological changes to the cells (Fig 6B and 6C). 
To more accurately model an environmentally relevant arsenic exposure, the 
lung epithelial cell line, BEAS-2B cells were exposed to 100 nM of arsenite, which did 
not affect cell viability (Fig. 6B) or grossly impact cell morphology (Fig. 6C). As a control 
for the culturing process and propagation of the cells, three sets of “passage matched” 
cultures were maintained in parallel to the three arsenite exposed cultures. After 24 
weeks in culture, all six cultures were subjected to Short Tandem Repeat (STR) profiling 
and were indistinguishable from the naïve BEAS-2B cells.  
Over the course of 24 weeks of 100 nM arsenite treatment, we sampled various 
time points (0, 6, 12, 18, and 24 weeks). Arsenite treated cells displayed an increase in 
EGFR expression, as well as in receptor phosphorylation (Fig. 7) as compared to 
passage matched control. Interestingly, in all three biological replicates, we observed the 
peak of basal EGFR phosphorylation at 12 weeks. This increase in basal EGFR activity  
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Figure 6. BEAS-2B cells exposed to acute arsenite have increased EGFR 
expression, altered cell morphology, and decreased viability.  
A. BEAS-2B cells were treated with or without EGF (10 ng/ml) for 10 minutes or exposed 
to 3 or 5 µM arsenite for 24 hours or no arsenic (-) as indicated. Cell lysates were 
prepared and equivalent number of cells (100,000 cells) were resolved by 7.5% SDS-
PAGE and immunoblotted for the presence of total EGFR, phosphorylated EGFR 
(pY1068), or α-tubulin as a loading control. Relative levels of EGFR and phosphorylated 
EGFR are indicated below the immunoblot. Shown is a representative blot from three 
independent experiments. B. BEAS-2B cells were exposed to varying concentrations (0-
100 µM) of sodium arsenite for 24 hours. Cell viability was assayed using Alamar Blue. 
Data are plotted as the average percentage of viable cells (compared to 0 µM sodium 
arsenite) ± SD (n=3). The concentration that is used in this study, 100 nM (10-7 M), does 
not decrease the cell viability. C. Representative micrographs showing the morphology 
of BEAS-2B cells with and without arsenite treatment. Upper row is a 4X magnification 






Figure 7. Chronic arsenite exposure induces EGFR expression and basal 
phosphorylation.   
BEAS-2B cells were treated without (-, even lanes 2-8) or with (+, odd lanes 3-9) 100 nM 
sodium arsenite for 6, 12, 18, or 24 weeks. As a positive control for EGFR tyrosine 
phosphorylation, naïve BEAS-2B cells were treated with 10 ng/ml EGF for 7 minutes 
(Lane 1). Cell lysates were prepared and equivalent number of cells (100,000 cells/lane) 
were resolved by 7.5% SDS-PAGE and immunoblotted for total EGFR expression and 
phosphorylation at tyrosine 1068 (pY1068). α-tubulin was used as a loading control. 










after chronic, low level arsenite exposure is in stark contrast to the absence of 
detectable receptor phosphorylation in cells treated with 3 or 5 µM arsenite for 24 hours 
(Fig. 6A). 
Chronic arsenite exposure increases cell migratory ability in a ligand-independent 
manner. 
To determine if there was a biological consequence of the increased basal EGFR 
activity from chronic arsenic exposure, we performed transwell migration assay to 
measure the migratory ability of naïve, acute arsenite treated, 24 weeks passage 
matched, and 24 weeks arsenite treated cells with and without EGF treatment (Fig. 8). 
Naïve, acute arsenite treated and passage matched cells exhibited approximately 2-fold 
increase in EGF dependent cell migration (Fig. 8). In contrast, BEAS-2B cells chronically 
treated with arsenite had an elevated rate of cell migration, and a small marginal 
increase with EGF treatment (Fig. 8) shown with the highest p value (p=0.1800). 
Chronic arsenite increases cell surface level of EGFR. 
Next, we investigated the localization of EGFR by measuring the cell surface 
levels. A fluorescently-tagged [phycoerythrin (PE)-conjugated] anti-EGFR antibody that 
recognizes the extracellular domain of the receptor was incubated with BEAS-2B cells to 
measure the cell surface level of EGFR. Fluorescent Activated Cell Sorting (FACS) 
determined the amount of cell-associated fluorescence, which served as an indirect 
measure of cell surface EGFR.  As compared to naïve, acute arsenite treated, and 
passage matched cells, cells chronically exposed to a low level of arsenite for 24 weeks 
had the highest median fluorescent intensity (MFI) values (Fig. 9A), indicating there were 
more cell surface EGFR. Acute arsenite (5 µM) exposed cells had a significant 
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Figure 8. Chronic arsenite exposure increases ligand-independent cell migration.   
Naïve, passage matched and 24 weeks arsenite treated cells were plated onto the upper 
chamber of a 0.8µm transwell and treated without or with 10 ng/mL EGF for 16 hours. 
The cells that migrated through the transwell were fixed with methanol and stained with 
Giemsa. Total 10 fields were imaged per sample to count the number of migrated cells. 
The numbers of migrated cells were then normalized to naïve cells without arsenite 
treatment. Individual symbols represent the fold change in the number of migrated cells 
from each experiment (n=4).  Data were analyzed by two-way ANOVA (Graphpad 
Prism).  
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Figure 9. Acute and chronic arsenite exposure differentially affect cell surface 
levels of EGFR.  
The cell surface level of EGFR was measured by incubating cells with phycoerythrin 
(PE)-conjugated EGFR antibody that binds to the extracellular domain of the receptor. 
Cell surface levels of EGFR were monitored by 5,000 cells/experiment by Fluorescent 
Activated Cell Sorting (FACS). A. Data are plotted from 24-week passage matched 
BEAS-2B cells that were treated without and with acute arsenite (5 µM), and 24-week 
chronic arsenite (100 nM). Individual symbols represent the mean fluorescence intensity 
(MFI) from each experiment (n=3). The bars and error bars represent the average MFI ± 
S.D. Data were analyzed by two-way ANOVA (Graphpad Prism). B. Cells from varying 
times of 100nM arsenite treatment were maintained in growth media (clear bars) or 
serum starved for 24 hours (grey bars) to washout ligands and cause receptors to 
redistribute to the plasma membrane. Individual symbols represent the mean 
fluorescence intensity (MFI) from each experiment (n=3). The bars and error bars 
represent the average MFI ± S.D. Data were analyzed by two-way ANOVA (Graphpad 
Prism).  
49	
decreased cell surface level of EGFR as compared to the chronically exposed cells 
(p=0.015). To characterize the level of intracellular EGFR, we serum starved the cells to 
redistribute intracellular receptors to the plasma membrane. Cell surface levels of the 
EGFR were examined using the PE-conjugated anti-EGFR antibody and FACS. The 
comparison of basal cell surface expression (in growth media) versus induced cell 
surface expression (serum starved) indicates there is a time-dependent increase in the 
total and percentage of intracellular EGFR (Fig. 9B).  
Chronic arsenite treatment increases TGFα expression. 
We next determined if chronic arsenic exposure increased transcription of the 
proximal components of the EGFR signaling axis. Acute arsenic exposure has been 
reported to increase expression of EGFR and its ligands [172, 277, 363, 400, 401].  
Quantitative PCR (qPCR) was used to assay mRNA levels of EGFR (Fig. 10A) and its 
closely related family member ERBB2 (Fig. 10B), as well as four endogenous EGFR 
ligands [epidermal growth factor (EGF), transforming growth factor-α (TGFα), 
amphiregulin (AREG), and β-cellulin (BTC)] (Fig. 10C-F). In acute arsenite exposure, 
only BTC mRNA level significantly increased  (p<0.0001). Over the course of 24 weeks, 
the EGFR mRNA levels remained indistinguishable from control cells; ERBB2 levels 
were elevated in one of the three biological replicates. The average TGFα mRNA level 
increased starting at 6 weeks of arsenite treatment and steadily climbed over the 24 
week time course and had the highest ligand mRNA level of all four ligands examined. 
The TGFα mRNA levels approached, but did not achieve, statistical significance (p= 
0.055, r2= 0.756) by the criteria set by Bryhn and Dimberg [402]. This is likely due to 
biological variability among the replicates (1.7 – 10.3 - fold over untreated cells). There 
were other changes in ligand mRNA. For instance, EGF mRNA levels increased in the  
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Figure 10. mRNA levels of the EGFR signaling axis in response to arsenic 
treatment.  
RNA was isolated from BEAS-2B cells treated without or with 100 nM sodium arsenite (0, 
6, 12, 18, or 24 weeks) and with 5 µM sodium arsenite (24 hours), and reverse 
transcribed to cDNA. Individual genes were amplified using qPCR and commercially 
available primers (Thermo Fisher). Graphs are separated by receptors [EGFR (A) and 
ERBB2 (B)] and ligands [Epidermal growth factor (EGF), Transforming growth factor-α 
(TGFα), Amphiregulin (AREG), and β-cellulin (BTC), (C-F)]. Data are plotted as the fold-
increase in gene expression (relative to 0 week) normalized to the average GAPDH 
levels. Each biological replicate is represented by the symbols. The bars indicate the 
average ± S.D.  (n= 3). 
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passage matched samples. In addition, AREG and BTC mRNA levels increased at 24 
weeks as compared to the untreated cells. Because the levels of these ligands 
increased only at the 24 week time point, it was not pursued because it did not match 
the kinetics of EGFR activity (Fig. 7). 
To determine if the increases in TGFα mRNA levels observed in chronic arsenite 
exposure were reflected by commensurate changes in TGFα protein levels, we 
performed an ELISA. At all four time points examined and all biological replicates, there 
was an increase in TGFα levels as compared to untreated cells (Fig. 11). These 
differences were most evident after 24 weeks of 100 nM arsenite exposure; TGFα levels 
in the media increased up to an average concentration of 58 pg/mL and achieved 
statistical significance (p= 0.0062). These data are consistent with a previous study that 
observed increased concentration of TGFα in urothelial cells of Mexican populations 
exposed to arsenic [403].  
Discussion 
Many studies have investigated how cellular toxicity and carcinogenesis are 
associated with arsenic exposure [172, 203, 219, 225, 234-238, 240-246, 277]. 
However, our study sets itself apart because it examines 1) the cells that accurately 
model lung epithelial carcinogenesis, 2) environmentally relevant arsenic concentrations, 
and 3) the kinetics of cellular changes. These findings more accurately reflect cancer 
development than do results from acute exposure. Our data expose important 
differences between acute and chronic arsenic exposure. These differences include cell 
morphology, cytotoxicity, EGFR activity and subcellular distribution indicating that the 
two treatment conditions induce EGFR expression using distinct mechanisms. The  
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Figure 11. Chronic arsenite significantly increases TGFα  protein levels. 
BEAS-2B cells were treated without or with 100 nM arsenite for 0 – 24 weeks as 
indicated. TGFα levels in the supernatant from passage matched and chronic arsenite 
treated cells were determined by ELISA. Data points represent the average TGFα 
concentration (of two technical replicates). Bars represent the mean concentration ± S.D. 
for each of the biological replicates (n=3). Data were analyzed using a two-way ANOVA 
(Graphpad Prism). 
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findings in this study are relevant to events occurring during arsenic exposure induced 
lung carcinogenesis. We investigated EGFR signaling in a model of chronic low level 
arsenite exposure in non-malignant human bronchial epithelial cells. We found that 24-
weeks of 100 nM arsenite exposure increased both EGFR expression and activity (Fig 
2), which contributed to increased cell migratory ability (Fig 3). In contrast to both naïve 
and passage matched cells, cells chronically treated with arsenite did not have an 
appreciable increase in its migratory ability with addition of EGF because receptor basal 
activity was already increased. At the same time, we observed an increase in the cell 
surface level of EGFR, as well as a progressive increase in TGFα levels (Figs. 4 – 6). 
This significant difference in the cell surface expression level of EGFR between acute 
and chronic arsenite exposure further highlights their possible differential mechanistic 
pathways. We also observed an increase in the amount of intracellular EGFR in cells 
chronically exposed to arsenite (Fig. 4B). This finding suggests that increased levels of 
TGFα not only triggers recycling of the receptor to induce increased cell surface level of 
EGFR, but also changes the dynamics of the EGFR trafficking, which diverts the 
ligand:receptor complex from the lysosome thus preventing degradation and signal 
termination [296-300], leading to increased basal EGFR activity (Fig. 2). It is well-
established that arsenic toxicities are highly dose- and time-dependent. The usual acute 
toxicity symptoms include diarrhea, vomiting, dehydration and hypotension, whereas 
chronic toxicity symptoms include cancer, cardiovascular disease, and respiratory 
disease. These symptoms support my findings of different impacts on BEAS-2B cells 
from acute and chronic arsenite exposure. 
In many ways, the ability of arsenic exposure to increase ligand production is not 
surprising. Acute high level arsenic exposure has been reported to increase mRNA 
expression for other endogenous EGFR ligands (i.e. HB-EGF) [172]. However, the 
previous experimental protocols that use acute high level arsenic exposure do not 
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accurately reflect what is observed in the human population. Future studies are 
warranted to determine whether chronic low level arsenic exposure differentially affects 
EGFR growth factor production and if those effects are cell type specific. 
It is noteworthy that the concentration of secreted TGFα in chronic arsenite 
treated cells is low (ranging from 4.5 pg/mL to 75.28 pg/mL). We noted this 
concentration is lower than the ligand’s affinity for the EGFR (Kd = 4.6 nM or 25,300 
pg/mL) [404]. We need additional studies to understand how these low concentrations of 
TGFα lead to EGFR activity. There are several studies that have observed malignant 
effects of TGFα in an autocrine manner in various types of cancer, including NSCLC 
[405-411]. Alternatively, TGFα may communicate with cells via exosomes as has been 
reported in other arsenic-transformed cells [412]. Isolating exosomes from chronic-
arsenic treated cells and measuring the levels of TGFα could provide additional 
information on the potential signaling mechanism. Also, additional studies are warranted 
to determine key events that lead to observed secretion of TGFα.  
Despite the need to reconcile some mechanistic details, our observation is 
consistent with the previous reports that nearly 50% of NSCLCs are characterized by 
increased TGFα [305]. Furthermore, there are associations between arsenic exposure 
and TGFα mRNA levels in skin tissues of mice chronically exposed to arsenic-
contaminated drinking water [363], as well as TGFα protein levels in bladder urothelial 
cells of individuals chronically exposed to arsenic-contaminated drinking water [403]. 
Further, as a mechanism to increased EGFR expression and activity, TGFα is logical 
from a receptor biology perspective. TGFα and EGF bind EGFR with comparable affinity 
at physiological pH, but TGFα binding is more sensitive to pH changes. For instance, 
50% of TGFα will dissociate from the EGFR at pH of about 6.8, whereas a pH of 5.8 is 
required to dissociate 50% of the EGF [298-300]. Thus, at the cell surface, both ligands 
stimulate receptor and the ligand:receptor complex is internalized. As the complex 
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moves to the early endosome, this more acidic compartment causes ligand dissociation 
and prevents the downstream signaling by directing the receptor to the lysosome.  
This transparent presentation of the data allows us to see that carcinogenesis is 
a stochastic process. Much the way not every smoker develops lung cancer, not every 
lung cell exposed to arsenic has the same increase in TGFα or EGFR expression. The 
kinetic data reveal overall trends, but the timing and magnitude of TGFα expression 
clearly varies from sample to sample. A longer and larger analysis may be useful for 
making clinical predictions.  
Chronic exposure of BEAS-2B cells to environmentally relevant concentrations of 
arsenic results in increased TGFα expression accompanied by elevated EGFR 
phosphorylation and increased cell surface EGFR, which is uniquely different from acute 
arsenic exposure. This study demonstrates different toxicological effects between acute 




CHRONIC ARSENIC EXPOSURE INCREASES EGFR-DEPENDENT CELL MOTILITY 
IN BEAS-2B CELLS 
Introduction 
Arsenic is an environmental contaminant that is ranked number one on the 
Agency for Toxic Substances and Disease Registry (ATSDR) Substance Priority List 
(ATSDR, 2017). Depending on the dose and duration of exposure, arsenic can have 
profoundly different toxicities. For instance, acute high dose arsenic exposure causes 
dehydration, hypotension, gastrointestinal distress (abdominal pain, vomiting, diarrhea), 
and renal failure [22]. In contrast, low dose chronic exposure is linked to diabetes, 
cardiovascular disease, dermal pathologies and respiratory diseases including lung 
cancer [22].  While the underlying pathophysiology associated with acute arsenic 
exposure is clear, the molecular changes accompanying chronic exposure have not 
been fully elucidated.  
The lungs are one of the primary tissues damaged by chronic arsenic exposure. 
In studies using female mice exposed to arsenic in utero and whole-life exposure [75], 
whole life exposure to arsenic caused approximately six-fold increase in the incidence of 
lung cancer.  These experimental data are supported by epidemiologic studies showing 
the highest incidence of lung cancer in countries that have high levels of arsenic in 
drinking water [102, 103, 124-126, 223, 413]. Despite these associations, there are no 
clearly defined mechanisms by which chronic arsenic exposure induces carcinogenesis. 
The goal of this research is to understand how chronic arsenic exposure changes lung 
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cells to make them more carcinogenic. Once identified, these cellular and molecular 
changes can be used for the diagnosis, prognosis, and treatment of lung cancer. 
BEAS-2B cells, non-malignant human lung bronchus epithelial cells immortalized 
by SV40 transfection, have proven to be an excellent model for arsenic-induced lung cell 
carcinogenesis [203, 381]. Studies from multiple labs have demonstrated that arsenic 
exposure (>15 weeks) can alter the cell’s phenotype to having an increase in 
carcinogenic phenotype, including anchorage independent cell growth [173, 175, 177, 
187, 190-193, 203, 204, 206] and increased cell motility [42, 192].  
In vitro studies, using concentrations that more accurately reflect those seen in 
human plasma generate a more relevant model of arsenic toxicity in humans. Reports in 
the literature include arsenic exposures up to 60 µM [178, 179]. For our studies, we used 
an arsenic concentration (100 nM) observed in the plasma of individuals that chronically 
consumed arsenic-contaminated drinking water [51]. Our previous study demonstrated 
that chronic low level of arsenic exposure increases Epidermal Growth Factor Receptor 
(EGFR) expression and basal activity. These changes were accompanied by increases 
in cell migration and TGFα secretion [42]. The EGFR is a receptor tyrosine kinase that is 
frequently overexpressed or hyperactivated in many cancers, including lung cancer [276, 
304, 305, 307, 309, 310, 394, 395]. Overexpression of the EGFR is associated with poor 
patient prognosis. Despite these clear links to lung cancer, how changes to the EGFR 
signaling axis impact lung epithelial cell biology is not fully understood. 
To better understand the cellular basis for the increased cell migration and how 
chronic arsenic exposure impacts the EGFR signaling pathway, we combined transwell 
migration assays, time-lapse live cell imaging microscopy, and biochemical assays to 
assess EGFR-mediated signaling in BEAS-2B cells.  Conditioned media from cells 
chronically treated with arsenite did not increase cell migration, rather, the conditioned 
media attenuated cell motility, suggesting the amount of secreted TGFα alone is not 
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sufficient to enhance cell migration. After 24 weeks of 100 nM arsenite exposure, we 
observed a two-fold increase in the cell speed, a 23% increase in cell persistence, and a 
30% increase cell protrusion length as compared to passage-matched cells. The 
increased cell motility of chronic arsenic treated cells reverted back to the basal rate of 
the passage-matched cells with AG1478, an EGFR inhibitor. However, increased cell 
persistence and the length of cell protrusion were not AG1478-dependent. Together, 
these data demonstrate that chronic low level arsenite exposure increases cell motility, 
persistence and protrusion length. 
Materials and methods 
Cell culture 
Human bronchial epithelial (BEAS-2B) cells were obtained from ATCC and grown in 
LHC-9 media (Gibco) supplemented with or without 100 nM sodium arsenite (Fisher 
Scientific) on a matrix of 10 µg/mL of fibronectin and 35 µg/mL of collagen (FNC Coating 
Mix, AthenaES). The sodium arsenite (arsenite) concentration was based on the 
average blood arsenic level in people who were exposed to high levels of arsenite in 
drinking water [51]. Cultures were grown in 5% CO2 at 37°C atmosphere. Three 
independent cultures of cells (3 with and 3 without 100 nM sodium arsenite) were 
maintained separately for 24 weeks. Cells were propagated by splitting at 1 x 106 cells/ 
10 cm dish every 3-4 days. Weekly, cells were frozen down at 1 x 106 cells/vial and 
stored in liquid nitrogen [42].    
Transwell assay 
The 8-µm polycarbonate membrane, 6.5-mm inserts (Corning, Inc., Corning, NY) were 
moisturized with serum-free media for 30 minutes at 37°C. After incubation, serum-free 
media containing the indicated concentrations of EGF and arsenic were added in the 
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lower chamber. Media from BEAS-2B cells grown in 100 nM arsenic for 24 weeks 
(conditioned media) was harvested after 24 hours at 37°C in 5% CO2. A density of 
100,000 BEAS-2B cells were plated in the upper chamber of the insert (The cells were 
harvested as described above). The cells were allowed to migrate for 16 hours at 37°C 
in 5% CO2. Migrated cells were then fixed in methanol, stained in Giemsa (3250-4, Ricca 
Chemical, Arlington, Texas), and counted under a microscope (TE-2000; Nikon, Tokyo, 
Japan) with a 20x objective. 
 
Time-lapse microscopy 
A Nikon TE2000 microscope equipped with control of temperature and CO2 levels was 
used. BEAS-2B cells were seeded at 2,000 cells/cm2 on an FNC-coated 6-well plate for 
at least 24 h prior to imaging. The images were obtained with a 10X objective every 15 
minutes over a 24 h period for 6 positions per condition in three biological replicates. A 
total of 30 cells per condition were tracked for cell migration and persistence, and 108 
cells per condition for protrusion lengths. The rate of cell migration and protrusion 
lengths were analyzed with ImageJ using Manual Tracking plugin and cell persistence 
was measured using the Chemotaxis and Migration Tool (Ibidi).  
 
Data Analysis  
Data were analyzed using Graphpad Prism 5.0 Software (Graphpad Software). 





Chronic arsenic treatment of BEAS-2B cells increases basal and EGFR stimulated cell 
migration. 
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In our previous study, we observed an increase in cell migration and production 
of TGFα from chronic arsenic exposure [42]. To determine whether the amount of 
secreted soluble ligands are sufficient to increase BEAS-2B cell migration, we performed 
a series of transwell migration assays using cells that were grown in 100 nM arsenite for 
24 weeks (24w) or passaged-matched (24PM) control cells (Fig. 12). Consistent with our 
previous study, chronic arsenic treatment resulted in a three-fold increase in cell 
migration as compared to the passage-matched cells (Fig. 12). Both cell lines were 
responsive to the endogenous EGFR ligand TGFα and exhibited a 2-2.5-fold increase in 
cell migration (Fig. 12). 
Next, we measured cell migration in response to conditioned media from BEAS-
2B cells grown in 100 nM arsenite for 24 weeks. Following treatment with conditioned 
media, cell migration was indistinguishable from the passage-matched control cells, but 
significantly decreased from the chronic arsenic treated cells (p=0.0464) (Fig. 12). 
Immuno-depletion with an anti-TGFα antibody did not significantly change cell migration 
from conditioned media treatment (Fig. 12).  Together, these data indicate that chronic 
arsenic treatment enhances basal and EGFR-stimulated cell migration, but the total, 
secreted TGFα from the conditioned media alone is not sufficient to mediate the 
enhanced migration. 
Chronic arsenic exposure increases the distance traveled and cell persistence. 
To better understand how chronic arsenic treatment increases cell migratory 
ability, we used time-lapse microscopy to monitor arsenic treated and passage-matched 
cells (Supplemental videos 1-6). We assessed cell movement by manually tracking cell 
location every 15 minutes in three biological replicates (6 fields/biological replicate), and 
marked each track with its endpoint on the trajectory plot to measure the distance 
traveled (Fig. 13A). Nearly 50% more cells traveled greater distance with chronic arsenic 
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Figure 12. Chronic arsenic treatment of BEAS-2B cells increases basal and EGFR 
stimulated cell migration. Passage matched and 24 weeks arsenic treated cells were 
plated onto the upper chamber of a 0.8 µm transwell. EGF-deficient (SF) media alone, 
SF media with 10 ng/mL TGFα, medium from chronic arsenic (24 weeks) treated cells 
(conditioned medium), and conditioned media incubated with TGFα neutralizing antibody 
were placed onto the bottom chamber and the cells were allow to migrate at 37°C for 
16h. The cells that migrated through the transwell were fixed with the methanol and 
stained with Giemsa. Total 10 fields were imaged per sample to count the number of 
migrated cells. The numbers of migrated cells were then normalized to passage 
matched cells without arsenic treatment. Individual symbols represent the fold change in 
the number of migrated cells from each experiment (n=3). Data were analyzed by one-
way ANOVA (Graphpad Prism). (* p< 0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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Figure 13. Chronic arsenic treatment of BEAS-2B cells increases the distance traveled 
and cell persistence. A. Each line represents a path of individual cell migrating from the 
site of its origin. The gray circle (radius of 100 µm) around the origin represents the 
threshold that was applied to measure the distance traveled. The cells were captured 
using a 10x phase-contrast objective lens and focused on the cell membrane protrusions. 
Six fields from each biological replicate were captured for every condition. A total of 10 
cells/each of the three biological replicate were analyzed for every condition. Cell 
movements were manually tracked every 15 minutes for 24 hours. B. The cell distance 
was analyzed with Chemotaxis and Migration Tool (Ibidi). C. Data are plotted as the cell 
persistency of 10 cells of each biological replicate (n=3). Data were analyzed by one-
way ANOVA (Graphpad Prism). (* p< 0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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exposure as compared to the passage-matched cells (Fig. 13A and 13B). The passage-
matched cells treated with TGFα had the same number of cells as the arsenic treated 
cells that traveled greater than 100 µm (Fig. 13A). Unlike the passage-matched cells, 
TGFα treatment did not affect the arsenic treated cells in distance traveled. AG1478, 
however, decreased the number of cells traveling greater than 100 µm in chronic arsenic 
treated cells by approximately 30% (Fig. 13A and 13B). Together, these data suggest 
that chronic arsenic exposure increases the distance traveled and it is EGFR-dependent. 
Another determinant of cell migration is persistence, or the sustained 
directionality of a cell. Enhanced cell persistence contributes to increased cell migration 
[414]. The closer the persistence value is to 1, the more directionality (linearity of 
migration) there is. There was 23% increase in the cell persistence of chronic arsenic 
treated cells as compared to the passage-matched controls (p=0.0773)  (Fig. 13C). 
Interestingly, the passage-matched cells significantly increased their persistence with 
TGFα treatment, but chronic arsenic treated cells stayed at the same level as those 
without TGFα (Fig. 13C). Treatment with AG1478 had no significant effect on cell 
persistence in either group (Fig. 13C).  
EGFR is necessary and sufficient for increasing cell speed in chronic arsenic treated 
cells. 
To determine whether the cell speed is consistent with the increased cell 
migration, we assessed the cell average velocity. Consistent with the transwell migration 
assays, we observed that chronic arsenic treated cells move approximately twice as fast 
as the untreated cells (Fig. 14A and 14B). We also examined whether the EGFR was 
driving the increase in cell speed, by treating cells with TGFα or AG1478, (Fig. 14A and 
14B, supplemental videos 3-6). TGFα increased the average cell speed in the passage-
matched cells approximately two-fold (Fig. 14Aii and 14B). TGFα had a more modest  
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Figure 14. EGFR is necessary and sufficient for increasing cell speed in chronic arsenic 
treated cells. BEAS-2B cells were grown with and without 100 nM arsenic for 24 weeks. 
A. Representative micrographs showing the cell motility of a single, representative 
BEAS-2B cells. At least after 24 hours of seeding of cells, BEAS-2B cells were treated 
with 10 ng/mL TGFα or 60 nM AG1478. The cells were captured using a 10x phase-
contrast objective lens and focused on the cell membrane protrusions. See videos in 
supplementary data.  Six fields from each biological replicate were captured for every 
condition. A total of 10 cells/each of the three biological replicate were analyzed for 
every condition.  Cell movements were manually tracked every 15 minutes for 24 hours. 
B. Images from the micrographs were quantified using NIH Image. Data are plotted as 
the average of velocity of 10 cells from each biological replicate (n=3). Data were 
analyzed by one-way ANOVA (Graphpad Prism). (* p< 0.05, **p<0.01, ***p<0.001, 
****p<0.0001). 
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relative fold-increase in the velocity of the arsenic treated cells (Fig. 14Av and 14B), but 
an overall greater velocity. In the presence of AG1478, the velocity of both passage-
matched and chronic arsenic treated cells reverted to the basal migration rate of 
passage-matched cells (Fig. 14B). 
 
EGFR is sufficient, but not necessary for increasing cell protrusion length in chronic 
arsenic treated cells. 
 
The sparse cell plating density needed for time-lapse imaging revealed striking 
changes in cell morphology. During the time-lapse imaging, we noted an increase in cell 
protrusion length in chronic arsenic treated cells (Fig. 15A), and that was not revealed at 
higher cell density. Cell protrusions are membrane extensions formed by actin 
polymerization and are associated with an increase in cell migration [415, 416].  We 
wanted to know whether chronic arsenic exposure increases cell protrusion length.  
Using the individual frames from our live-cell imaging, we measured cell 
protrusion lengths of each biological replicate in both untreated and arsenic treated cells. 
Cell protrusion length was measured as the distance from the outermost portion of the 
cell membrane to the cell center. All cells were measured when they were at their 
maximal length during the 24-hour video.  
We observed a 30% increase in cell protrusion length in cells chronically treated 
with arsenic, as compared to the passage-matched cells (Fig. 15A and 15B). TGFα 
significantly increased cell protrusion length in both untreated and arsenic treated cells 
(Fig. 15A and 15B). Unlike cell speed, there was no apparent difference in the length of 
cell protrusion when chronic arsenic treated cells were treated with AG1478 (Fig. 15B).  
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Figure 15. EGFR is sufficient, but not necessary for increasing cell protrusion length in 
chronic arsenic treated cells. BEAS-2B cells exposed with and without 100 nM arsenic 
for 24 weeks. A. Representative micrographs showing the cell protrusions of BEAS-2B 
cells. The cells were captured using a 10x phase-contrast objective lens. Six fields from 
each biological replicate were captured for every condition. A total of 36 cells were 
analyzed for each of the three biological replicates for each condition. Cell protrusion 
length was measured as the distance from the leading edge of the cell membrane 
protrusion to the cell mid-body. All cells were measured when they were at their maximal 
length during the 24-hour video. The images were captured every 15 minutes for 24 
hours.  B. Data are plotted as the maximum lengths of cell protrusion of 36 cells of each 
biological replicate (n=3) Data were analyzed by one-way ANOVA (Graphpad Prism). (* 
p< 0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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Discussion 
Arsenic is a well-established environmental contaminant that is strongly 
associated with the development of chronic lung diseases, including lung cancer [102, 
103, 123, 128, 130-132]. Despite this association, there is a significant need to better 
understand the mechanism of arsenic-induced lung carcinogenesis and leverage these 
insights for developing diagnostic and therapeutic tools. In our earlier study, we 
observed an increase in EGFR expression and activity levels, as well as an increase in 
soluble TGFα secretion from chronic arsenic exposure [42]. TGFα is a unique EGFR 
ligand as it promotes receptor recycling and increases the steady-state levels of the 
EGFR. Here, we investigate whether these cellular changes are sufficient to increase 
cell migration.  
Our transwell migration assays show that the amount of secreted TGFα in the 
conditioned medium is not sufficient to increase cell migration (Fig. 12). The conditioned 
media were unable to increase cell migration in either passage-matched or cells 
chronically treated with arsenic. This was not entirely unexpected because the 
concentrations produced (average concentration of 58 pg/mL) [42] are approximately 
400-fold less than the KD for the receptor (4.6 nM or 25,300 pg/mL) [404]. It is likely that 
TGFα signals in an autocrine or paracrine fashion, and collecting the media disrupts the 
higher local concentrations at the point of ligand production and receptor activation. 
However, we cannot rule out the possibility that there are other components that 
contribute to cell motility in chronic arsenic treated cells. 
Time-lapse microscopy allowed us to measure individual cellular changes 
associated with increased cell migratory ability – namely, cell distance traveled, 
persistence, speed, and protrusion length. These parameters were enhanced in chronic 
arsenic treated cells, as compared to the passage-matched cells (Supplementary Videos 
1-6). While the passage-matched cells increased in cell distance traveled, persistence, 
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speed, and protrusion length in response to TGFα, only cell speed and protrusion 
lengths were enhanced with TGFα in the cells chronically treated with arsenic. This may 
be due to the enhanced levels of EGFR activity and the addition of more growth factor 
cannot further increase cell persistence, which is already near the maximal effect.  
Because we observed an increase in cell invasion potential from chronic arsenic 
exposure, it is worth measuring these parameters on cancerous cells to compare their 
functional readouts to the chronic arsenic exposed cells. These findings will help us to 
identify possible therapeutic target to mitigate arsenic toxicity.  
Interestingly, the addition of the EGFR inhibitor, AG1478, decreased the distance 
traveled and cell speed in cells chronically treated with arsenic, but did not have a 
statistical effect on persistence or protrusion lengths. While these parameters are related 
to cell invasion, cell protrusion length, particularly, is strongly associated with 3D 
invasion behaviors [417]. A study has reported that a glioblastoma cell line, U87, has the 
longest average protrusion length into the collagen and the highest invasion ability, as 
compared to the other typical glioblastoma cell lines [417]. This study highlights the 
importance of the cell protrusion length and its contribution to metastatic capacity. 
Because we have only observed a statistical effect of AG1478 on cell speed, but not on 
cell persistence or protrusion lengths in cells chronically treated with arsenic, one 
explanation is that EGFR-dependent mechanisms do participate in invasion, but 
additional mechanisms are present. Alternatively, chronic arsenic exposure could 
stimulate intrinsic reprogramming processes to allow cells to acquire enhanced 
persistence and cell protrusions, which are commonly observed in malignant cells [418-
423]. For instance, cell membrane protrusions are dependent on the Rho family of 
GTPases, such as Rac1 and RhoA [424-427]. Furthermore, studies have shown that 
arsenic increases both expression and activity levels of Rac1 [240, 428], which is known 
to promote actin polymerization and membrane protrusion. Thus, it is worth investigating 
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how the effects of more physiologically relevant concentration of arsenic exposure might 
impact the Rho family of GTPases. This would help elucidate the mechanism by which 
chronic arsenic exposure promotes cell protrusions and persistence. Further, integrin 
receptor signaling is associated with cytoskeletal rearrangement [429, 430], and there is 
a paucity of research studying the association between chronic arsenic exposure and 
integrin receptor signaling. Particularly, fibronectin receptor is known to be involved in 
polarized cell protrusions [431]. Because we observed EGFR-independent mechanisms 
of chronic arsenic exposure-induced cell persistence and protrusions, it is worth 
investigating how a chronic low level of arsenic exposure impacts integrin receptors, 
specifically fibronectin receptor, and exploring possible arsenic-induced crosstalk 
between fibronectin receptor and EGFR to enhance cell migratory ability.  
 
Conclusion 
Despite a clear association between chronic arsenic exposure and lung cancer, 
little is understood about the molecular changes that lead to carcinogenesis. To better 
understand the cellular basis, we assessed EGFR dependency in cell speed, 
persistence and protrusion length in chronic arsenic treated BEAS-2B cells. We 
observed that chronic arsenic exposure increases cell speed in an EGFR-dependent 
manner, but increased cell persistence and protrusion lengths are not dependent on 
EGFR. Together these changes provide a better understanding of how non-malignant 
human lung epithelial cells acquire cancer-like phenotypes from chronic arsenic 
exposure. We anticipate that this study opens up new avenues for identifying potential 






DISCUSSION AND FUTURE DIRECTIONS 
A. Restatement of Research Goals 
There is a strong association between chronic arsenic exposure and EGFR 
overexpression, however the exact mechanism of chronic arsenic exposure-induced 
EGFR overexpression, as well as of chronic arsenic exposure-induced lung cancer 
development still remain elusive. This work provides novel mechanisms to chronic 
arsenic-induced EGFR overexpression, as well as functional effects of chronic arsenic 
exposure that contributes to lung cancer development. Further, this study differentiates 
the impact of acute and chronic arsenic in human lung epithelial cells.  
B. Summary of Findings 
To determine whether chronic exposure to an environmentally relevant level of 
arsenic alters EGFR expression, we performed immunoblot. Both EGFR expression and 
its activity levels were measured in acute and chronic arsenic exposure conditions. 
Unlike acute arsenic exposure, chronic exposure increased both expression and activity 
levels of EGFR. The enhanced EGFR activity was supported by increased cell migratory 
ability. We also performed flow cytometry to identify the localization of EGFR. We 
observed an increase in the cell surface level of EGFR from chronic arsenic exposure. 
To understand the biochemistry behind this phenomenon, we performed RT-qPCR to 
measure mRNA levels of a subset of EGFR ligands in both acute and chronic arsenic 
conditions. We observed a time-dependent increase in TGFα mRNA levels from chronic 
arsenic exposure, but from acute exposure, there was a significant increase in BTC. 
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These data further highlight different cellular impact of acute and chronic arsenic 
exposures and support different toxicological effects of arsenic in humans (Table 1). To 
determine whether protein levels are consistent with the mRNA level, we performed 
ELISA and observed an increased secretion of TGFα from chronic arsenic exposure.  
In addition to identifying chronic arsenic exposure-induced secretion of TGFα, we 
wanted to investigate if the amount of secreted TGFα from chronic arsenic exposure was 
sufficient to induce cell migration. First, we performed a series of transwell migration 
assays using conditioned media. We observed that the amount of secreted TGFα is not 
sufficient to increase cell migration. Next, we wanted to understand of the cellular level 
of the increased cell migratory ability from chronic arsenic exposure. We used time-lapse 
live cell imaging microscopy to measure the distance traveled, cell persistence, speed, 
and cell protrusion length. Consistent with our previous study, as well as our transwell 
migration assay, we observed an increase in the distance traveled and average cell 
velocity in chronic arsenic treated cells in an EGFR-dependent manner. Therefore, 
EGFR is necessary and sufficient for increasing cell speed in chronic arsenic treated 
cells. Because cell persistence contributes to increased cell migration [414], we 
measured cell persistence in chronic arsenic treated cells. We hypothesized an increase 
in persistence in chronic arsenic treated cells, because faster cells turn less as speed 
stabilizes cell directionality. Expectedly, we observed an increase in cell persistence in 
chronic arsenic treated cells, but it was not EGFR-dependent, as neither TGFα nor 
AG1478 was able to affect the cell persistence in chronic arsenic treated cells. During 
time-lapse imaging, we noted long cell protrusions in chronic arsenic treated cells. Cell 
membrane protrusions are strongly associated with cell migration [415, 416], as well as 
3D cell invasion [417]. Together, these data show that chronic arsenic increases cell 
migration in both EGFR-dependent and –independent mechanisms. A schematic 
diagram that summarizes the project is shown in Figure 16. 
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Figure 16. A schematic diagram that summarizes the impact of chronic arsenic on 
the EGFR signaling axis and on cell migration.  
73	
C. Significance of Findings 
There is a direct association between arsenic in drinking water and cancer 
development, including non-small cell lung cancer (NSCLC). Proposed mechanisms of 
arsenic carcinogenicity include, oxidative stress [217-223], miRNA expression [225, 228, 
229], aneuploidy [235], and activation of oncogenic pathways [172, 236-252]. However, 
a clear arsenic-induced carcinogenic mechanism still remains elusive. Both a previous 
study and our study show that acute arsenic exposure (1-10 µM) induces 
overexpression of the EGFR [42, 277]. However, how chronic arsenic exposure affects 
the EGFR expression and its signaling axis remains unclear.  
This study is significant because it broadened our understanding of the effect of 
chronic arsenic exposure on the EGFR signaling axis, contributing to overexpression of 
EGFR. We observed that chronic arsenic exposure increases TGFα expression level, 
resulting in an increase in steady state level of EGFR. These findings suggest that TGFα 
level can be served as a biomarker for the arsenic exposure-induced cancer 
development. Because an increase in TGFα level is not specific to lung cancer, further 
studies are needed to identify cancer type-specific biomarker. These findings also 
suggested that acute and chronic arsenic exposure act differently on the EGFR signaling 
axis, supporting different toxicological effects observed in humans between acute and 
chronic exposure. Further, we assessed the functional effects in cells chronically treated 
with arsenic using a time-lapse microscopy. We observed that both EGFR-dependent 
and –independent mechanisms contribute to an increase in cell invasion potential from 
chronic arsenic exposure. Together, the findings reported in this dissertation are 
significant because they help develop strategies to mitigate the effect of arsenic toxicity, 
which align with the National Institute of Environmental Health Sciences mission of 
discovering the impact of environmental toxicants on people to promote healthier lives.  
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D. Strengths and Weaknesses 
i. Strengths
A major strength of this work is in its use of a physiologically relevant level of 
arsenic and exposure time. There are a variety of cell lines, arsenic concentrations and 
exposure times used in many in vitro studies. The variations in arsenic concentrations 
make direct comparisons challenging; however, the majority of these studies reflect the 
differences in the level of arsenic exposure across the globe. The range of 
concentrations is consistent with the notion that there is no “correct” arsenic 
concentration or consensus in the field. However we wanted to generate the most 
biologically meaningful in vitro studies. The arsenic concentration of 100 nM reflects the 
average blood arsenic level in people who were exposed to high levels of arsenic in 
drinking water [51]. Also, deleterious effects of arsenic are highly dependent not only on 
the dose but also on duration of exposure, as acute and chronic toxicities present 
differently. To mimic human chronic exposure to arsenic, we treated BEAS-2B cells for 6 
months, as chronic exposure is defined as an exposure lasting 6 months to a lifetime, 
according to the EPA Terminology Services [20]. Also, BEAS-2B cells require specific 
growth medium and coated plates. Many studies, however, have used incorrect media 
(added FBS), and/or the cells were not cultured in collagen-coated plates. All these 
factors are known to alter cell morphology, increase mesenchymal associated gene 
expression, decrease in epithelial associated gene expression, and increase sensitivity 
to arsenic [432, 433]. Thus, the cells with these altered characteristics can lead to 
erroneous data to assess and predict toxicological response due to changes in 
sensitivity of the cells. We followed the ATCC recommended guidelines and protocols for 
choosing a proper cell culture media and growth conditions for BEAS-2B cells and 
ensured by STR mapping after completion of 24 weeks in all three biological replicates. 
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Another strength of this work is we were able to assess differential impacts of 
acute and chronic arsenic exposure in the EGFR signaling axis, as well as cellular 
changes (cell motility, persistence, protrusion length) in BEAS-2B cells chronically 
treated with arsenic. There are a scarce number of studies that analyze both acute and 
chronic arsenic exposures. Our study supports different toxicological effects observed in 
humans from acute and chronic arsenic exposure and suggests possible differential 
mechanistic pathways of acute and chronic arsenic exposures.  
Also, we observed an increased secretion of EGFR endogenous ligand TGFα 
from chronic arsenic exposure, which supports a study that observed overexpression of 
both EGFR and TGFα level in NSCLC patients [305]. We anticipate that this study will 
contribute to identifying potential therapeutic targets for arsenic-induced lung diseases. 
ii. Weaknesses 
 One of the few limitations of this work is in its use of one cell line and not using 
any animal models. At present, a number of journals require using multiple cell lines to 
support the scientific findings. Using multiple cell lines will further strengthen the value of 
toxicological studies in vitro and bolster animal and clinical studies. Animal models are 
widely used in toxicological studies as the target sites of arsenic carcinogenetic effects in 
animals are concordant with most of the human targets of arsenic and reflect human 
toxicological responses. Further, due to the nature of toxicokinetics, the cell culture 
responds differently from the human organism even with the same concentration of 
arsenic. However, it is important to note that in vitro models provide fundamental 
platform for animal studies and tools for elucidating the molecular mechanisms 
underlying arsenic toxicity and carcinogenesis.  
 Lack of carcinogenicity assessment is another weakness of this work.  Multiple 
labs perform anchorage-independent assay to assess carcinogenicity of arsenic treated 
cells. The soft agar assay is commonly used to monitor anchorage-independent growth 
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of cells. We have performed soft agar assay and we used B30TIC cells, a tumor cell line 
for epithelial cells, as our positive control. We observed colony formation in B30TIC 
cells, however, we were not able to observe any colony formation even after 29 weeks of 
arsenic treatment in BEAS-2B cells. Nonetheless, there are several studies that observe 
transformation of BEAS-2B cells from arsenic exposure. Though many studies do not 
use a proper cell culture media and follow the ATCC recommended growth conditions 
for BEAS-2B, there are a few studies that used appropriate media, as well as coating 
condition for BEAS-2B cells and have successfully transformed BEAS-2B cells with 
chronic arsenic exposure, thus it is crucial that this work be repeated. Alternatively, 
xenograft models could have been used to assess carcinogenicity of chronic arsenic 
treated cells to strengthen our findings. 
An inherent limitation of in vitro experiments, when studying arsenic toxicological 
effects, is that not all cells receive the same level of arsenic-induced damages. As the 
cells divide, more damaged cells proliferate faster and tend to overcome the host’s 
regulatory mechanism, which results in selection. Therefore, the chronic arsenic treated 
cells in our study may not represent the whole population of cells that were initially 
exposed to arsenic, but a subpopulation of cells that had the most damage from arsenic 
exposure and survived the host’s regulatory mechanism.  
E. Future Directions 
In our study, we observed overexpression of EGFR from chronic arsenic 
exposure and the overexpression of EGFR is widely used as a biomarker for a variety of 
diseases, including lung cancer. However, there is a paucity of research identifying 
biomarkers for early and accurate diagnosis. For future study, I am specifically interested 
in assessing molecular epidemiologic mechanistic pathway markers for environmental 
toxicants-induced adverse effects on fetal growth and child neurodevelopment.  
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Methylation steps have been characterized as a critical arsenic metabolism 
process. Because methylation process is important in elimination of arsenic from the 
systemic circulation, it is easy to incorrectly assume that methylation is a detoxification 
process of arsenic as it enhances excretion of arsenic. However, all arsenic metabolites 
are toxic to different degrees [59, 60, 68, 69]. High ratios of MMA/DMA are indicators of 
a reduction in arsenic methylation [434]. A study has shown a strong inverse relationship 
between urinary MMA levels and gestational age, birth weight, and newborn length 
[434]. However, whether these observed differences in gestational age, birth weight, and 
newborn length affect the later life health had remained elusive, until a recent case-
control study uncovered arsenic methylation capacity is associated with developmental 
delays [435]. Further, reduction in arsenic methylation capacity is associated with 
arsenic-induced ROS generation and oxidative DNA damage. In a recent study, there 
were increased levels of 8-nitroguanine not only in women who were exposed to arsenic 
during pregnancy, but also in newborns and in children through their early life [436]. 
Delineating a direct role of arsenic-induced ROS generation in child development and 
assessing associations between newborns’ arsenic methylation capacity and oxidative 
DNA damage would help identify potential biomarkers that would allow early prediction 
of developmental delays and children’s health. Interestingly, a cohort study in Mexico 
observed pregnant women with higher DMA levels (88%) as compared to general 
populations exposed to arsenic around the world (60-80%) [434, 437, 438]. Because a 
high ratio of DMA/MMA is usually indicative of increased arsenic methylation capacity, 
these observed high levels of DMA might have a protective effect for both mother and 
fetus. Therefore, it is worth investigating the inherent differences in population 
characteristics, such as genetic polymorphisms and nutritional factors.  
Because arsenic targets many different signaling pathways, there are many 
proteins that are strongly associated with arsenic exposure that can be bio-monitored for 
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early diagnosis. Aquaglyceroporins (AQP) are transmembrane channel proteins involved 
in transferring small solutes, such as arsenite. A study has shown an increase in AQP9 
expression from arsenic exposure and its association with lower birth weight [439]. 
Because AQP9 serves as an arsenic transporter, it is presumed that increased AQP9 
increases arsenic uptake, resulting in deleterious effects in fetal growth. However the 
direct relationship still remains unclear, and there are other small solutes that AQP9 
transfers, such as glycerol. Thus, it would be important to identify biomarkers that are 
exclusively induced in response to arsenic exposure.  
The original goal of this research was focused on elucidating the effects of 
chronic arsenic exposure in EGFR signaling axis. In the process of pursuing this 
question, we have uncovered possible mechanisms by which chronic arsenite exposure 
acts to increase EGFR expression, as well as its activity, and to increase cell migratory 
ability. There are several proposed mechanisms for chronic arsenic-induced lung cancer 
development. But the clear mechanism still remains elusive. In this study, we 
demonstrate possible different mechanistic pathways between acute and chronic arsenic 
exposure and assessments of the cellular changes in lung cells chronically exposed to 
arsenic. For future work, we will leverage these insights to identify therapeutic targets 
and biomarkers to enhance current therapy.  
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